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Abstract 
High-risk neuroblastoma presents a significant therapeutic challenge because the 
5-year survival rate remains less than 30% despite the use of surgery, multi-agent 
chemotherapy, radiation, and autologous bone marrow transplant. Novel therapeutic 
modalities are under development. The camptothecin analogs topotecan and irinotecan 
have been identified as successful cytotoxic agents. For topotecan, pharmacokinetically 
guided dosing to achieve a systemic exposure associated with preclinical anti-tumor 
activity in neuroblastoma xenograft models is feasible and has elicited favorable 
responses in children with high-risk neuroblastoma. However, some children with high-
risk disease did not respond to the putatively effective topotecan systemic exposure. 
These children represent a subset of the disease intrinsically resistant to topotecan. 
Furthermore, mRNA expression of the adenosine triphosphate (ATP)-binding cassette 
(ABC) transporters P-glycoprotein (Pgp) and multidrug resistance associated protein 1 
(MRP1), which efflux many drugs used in neuroblastoma therapy, has been implicated in 
poor outcome in neuroblastoma. Therefore, the purpose of our studies was to determine 
the role of ABC transport protein expression in neuroblastoma resistance to the 
camptothecin analogs topotecan and irinotecan. 
Initially studies focused on determining the expression of ABC transporters for 
which the camptothecin analogs are substrates in neuroblastoma cell lines. By western 
blot analysis we demonstrated MRP4 and Pgp expression in neuroblastoma cell lines 
relatively resistant to topotecan (e.g., NB1691), but not in cell lines sensitive to topotecan 
(e.g., NB1643). In contrast, MRP1, MRP2, and breast cancer resistance protein (BCRP) 
expression did not discriminate between sensitive and resistant cell lines. To determine 
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the functional contribution of both MRP4 and Pgp in neuroblastoma, we used RNA 
interference (RNAi) to silence MRP4 and Pgp expression in NB1691. Long term, stable 
expression of retroviral vector mediated short hairpin RNA (shRNA) reduced MRP4 and 
Pgp expression. Isogenic cell lines with reduced expression of MRP4 and Pgp exhibited 
an increase in sensitivity to both topotecan and SN-38, the active moiety of the prodrug 
irinotecan. In addition, we overexpressed MRP4 in NB1643, which resulted in increased 
topotecan resistance. 
The NB1691 cell lines with reduced MRP4 expression were subsequently 
transplanted as xenografts into severe combined immunodeficiency (SCID) mice to 
determine the effect of MRP4 expression on the in vivo response to topotecan. 
Unexpectedly, MRP4 silencing did not persist in vivo, and none of the xenograft models 
responded to topotecan. However, MRP4 expression was associated with failure to 
respond to topotecan, supporting the hypothesis that MRP4 mediates resistance to 
topotecan. 
Finally, we determined the ABC transporter expression profile in primary tumor 
specimens from patients with high-risk neuroblastoma who were treated with 
pharmacokinetically guided topotecan. Of the 14 specimens studied, MRP4 was 
expressed in 2 samples, and Pgp was expressed in 4 samples. BCRP was not expressed in 
any of the neuroblastoma cell lines in vitro, but immunohistochemical analysis 
demonstrated BCRP expression in nine primary neuroblastoma samples. Although we 
predicted that MRP4 and/or Pgp expression would be associated with failure to respond 
to topotecan, results of immunohistochemical analysis did not demonstrate such an 
association. 
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The results of the in vitro studies demonstrate that MRP4 and Pgp confer 
resistance to topotecan and SN-38. In the xenograft studies, MRP4 expression was 
associated with failure to respond to topotecan. However, this phenotype was not 
recapitulated in children treated with topotecan. These results may be confounded by 
small sample size and timing of sample acquisition. Further investigation of the role of 
ABC transporters in children with neuroblastoma who receive either topotecan or 
irinotecan may be warranted. In addition to the camptothecin analogs, patients will 
receive other drugs effluxed by the ABC transporters (e.g., doxorubicin, vincristine, 
etoposide, and cyclophosphamide). Therefore, analyzing ABC transporter expression by 
immunohistochemistry in diagnostic tumor specimens may help to select agents not 
subject to efflux by ABC transporters expressed in the tumor. However, eliminating 
drugs effluxed by ABC transporters from the treatment regimen creates a potential gap in 
therapy and may reduce drug intensity. Therefore, further rational design and 
development of drugs that evade ABC transporter-mediated efflux, and potentially other 
resistance mechanisms in neuroblastoma, is also warranted. 
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Chapter 1. Introduction 
Neuroblastoma is the most common extracranial solid tumor of childhood, 
accounting for 7-10% of all childhood malignancies (1,2). Most patients present with 
metastatic disease and have a poor prognosis (2,3). Therefore, improving therapy for 
children with neuroblastoma is a major focus of ongoing preclinical and clinical research. 
Results of work in one such area, overcoming multi-drug resistance, suggest that it may 
be one of the many barriers to improving survival in children with this disease. The 
molecular basis of multi-drug resistance in neuroblastoma is likely to be multifactorial, 
caused by alterations in DNA repair pathways (4), increased intracellular detoxification/ 
inactivation of drugs (5,6), alterations in cell survival pathways (7,8), decreased binding 
of drugs to the intended target (9), or increased efflux of chemotherapeutic agents from 
cells. 
Available data suggest that in neuroblastoma cells increased efflux may be a 
determinant of resistance to chemotherapy. In solid tumor cells, drug efflux can be 
mediated by members of the ABC transport protein superfamily. P-glycoprotein (Pgp) 
and multi-drug resistance associated protein 1 (MRP1), both members of the ABC 
transporter superfamily, are expressed in tumor specimens from children with 
neuroblastoma (10,11,12). High Pgp and/ or MRP1 expression in neuroblastoma is 
associated with poor prognosis. Also associated with poor prognosis is MYCN, a 
transcription factor often amplified in neuroblastoma (13). The observation that MYCN 
regulates the expression of several ABC transporters suggests two independent 
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prognostic indicators for poor outcome: MYCN amplification and ABC transporter 
expression (14). 
Several drugs used in neuroblastoma therapy, including doxorubicin, vincristine, 
and etoposide (15,16), are ABC transporter substrates.  The camptothecin analogs 
topotecan and irinotecan are emerging as useful components of neuroblastoma therapy 
(15,17) and are also substrates for ABC transporters (18). Therefore, the major focus of 
this dissertation will be to assess the role of ABC transporter expression in resistance to 
the cytotoxicity of topotecan and irinotecan in vitro, in vivo, and in children with 
neuroblastoma. Expression of ABC transporters for which these camptothecin analogs 
are substrates will be characterized in neuroblastoma cell lines demonstrating a spectrum 
of sensitivity to these compounds. Molecular techniques including exogenous 
overexpression and RNA interference (RNAi) will be used to evaluate the functional 
contribution of individual transporters to drug resistance in vitro by quantitating 
camptothecin analog sensitivity in isogenic cell lines. In addition, xenografts in mice will 
be generated using these isogenic cell lines to assess the response to camptothecin 
analogs. Lastly, primary tumor specimens from patients with high-risk neuroblastoma 
will be analyzed to identify potential associations between clinical response to topotecan 
and ABC transporter expression.  
1.1 Neuroblastoma 
1.1.1 Epidemiology 
Neuroblastoma is the most common cancer in children younger than one year 
(19). Furthermore, neuroblastoma is the most common extracranial solid tumor of 
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childhood. Neuroblastoma can arise from any tissue of sympathetic origin, but the 
adrenal gland is the most common primary site. In the United States the annual 
neuroblastoma incidence among children less than 15 years of age is 9.7 cases per million 
(20). Neuroblastoma occurs at similar rates in both males and females, but a slightly 
higher predominance is reported in whites than in blacks (10.2 versus 7.8 cases per 
million, respectively). Most commonly neuroblastoma occurs in children younger than 
two years. The median age at diagnosis is 22 months (21). Between 1985 and 1988 the 
overall 5-year survival for children with neuroblastoma was 58% (1). However, only 34% 
of children diagnosed with stage 4 neuroblastoma are long-term survivors (22). The 
biological mechanisms that contribute to the poor survival in children with advanced 
stage neuroblastoma are a subject of intense research. ABC transporter mediated efflux of 
chemotherapeutic agents from tumor cells is among the many potential causes of poor 
survival in children with neuroblastoma. Therefore, the major focus of this dissertation 
will be on the role of ABC transporters in high-risk neuroblastoma, in particular, the role 
of these proteins as determinants of sensitivity or resistance to the camptothecin analogs 
topotecan and irinotecan. 
1.1.2 Diagnosis 
Patients with neuroblastoma can present with abdominal discomfort, fullness, or 
pain (23). Hypertension, sweating, flushing, and tachycardia may also be present, 
depending on tumoral catecholamine secretion. Before 1988 no uniform criteria for 
neuroblastoma diagnosis, staging, and response evaluation existed, making it difficult to 
compare clinical studies of neuroblastoma(24). From 1988-1993 the major pediatric 
oncology groups from the United States, Europe, and Japan proposed consensus criteria 
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for neuroblastoma diagnosis, staging, and response evaluation (25). Tumor stage and 
other prognostic indicators (e.g., MYCN status, DNA ploidy, Shimada Histology) are 
assessed in order to stratify patients into risk groups which determine the course of 
therapy. 
1.1.3 Prognostic indicators and risk adapted therapy 
1.1.3.1 Neuroblastoma disease stage as a prognostic indicator 
Therapeutic modalities and treatment intensity are determined based upon a 
child’s risk for a poor outcome (i.e., low, intermediate, and high-risk disease). Our study 
focuses on high-risk neuroblastoma. Factors used to stratify neuroblastoma patients into 
low, intermediate, or high-risk neuroblastoma (Table 1.1) include disease stage according 
to the international staging system for neuroblastoma (INSS), a patient’s age, MYCN gene 
copy number, Shimada histology, and DNA index (2). The patient’s age at diagnosis and 
INSS stage are the two most important prognostic variables in childhood neuroblastoma. 
The current standardized INSS defines six possible stages (Table 1.2) of childhood 
neuroblastoma based upon tumor confinement, resection, metastasis to lymph nodes, 
bone marrow, liver, or other sites (2). Children with advanced neuroblastoma (i.e., stage 
3 or 4) have a poor prognosis. 
1.1.3.2 Age at neuroblastoma diagnosis as a prognostic indicator  
The correlation between young age at diagnosis (i.e., younger than 12-18 months) 
and good prognosis is well documented (26). Recent evidence suggests that children 
younger than 18 months have a more favorable prognosis than older children diagnosed  
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Table 1.1 Neuroblastoma risk group stratification. 
 
INSS 
Stage 
Age 
(Years) 
MYCN Status Shimada 
Histology 
DNA Index Risk Group 
1 0-21 Any Any Any Low 
2A/2B <1 Any Any Any Low 
 ≥1-21 Non-amplified Any NA Low 
 ≥1-21 Amplified Favorable NA Low 
 ≥1-21 Amplified Unfavorable NA High 
3 <1 Non-amplified Any Any Intermediate 
 <1 Amplified Any Any High 
 ≥1-21 Non-amplified Favorable NA Intermediate 
 ≥1-21 Non-amplified Unfavorable NA High 
 ≥1-21 Amplified Any NA High 
4 <1 Non-amplified Any Any Intermediate 
 <1 Amplified Any Any High 
 ≥1-21 Any Any NA High 
4S <1 Non-amplified Favorable >1 Low 
 <1 Non-amplified Any =1 Intermediate 
 <1 Non-amplified Unfavorable Any Intermediate 
 <1 Amplified Any Any High 
 
Source:  Castleberry, RP. Neuroblastoma, Eur J Cancer, 33: 1430-1437, 1997. 
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Table 1.2 International staging system for neuroblastoma. 
 
Stage Description 
Stage 1 
Localized tumor confined to area of origin; complete gross resection, ± 
microscopic residual disease; ipsilateral and contralateral lymph nodes 
are tumor negative 
Stage 2A Unilateral with incomplete gross resection; ipsilateral and contralateral lymph nodes tumor negative 
Stage 2B Unilateral with complete or incomplete gross resection; ipsilateral lymph node tumor positive; contralateral lymph node tumor negative 
Stage 3 
Tumor infiltrates across midline ± regional lymph node involvement; or 
unilateral tumor with contralateral node involvement; or midline tumor 
with bilateral lymph node involvement 
Stage 4 Tumor dissemination to distant lymph nodes, bone marrow, liver, or other organ except as in 4S 
Stage 4S 
Localized primary tumor as for Stage 1 or 2 with dissemination to liver, 
skin, or bone marrow with <10% nucleated marrow cells being tumor 
cells 
 
Source:  Castleberry, RP. Neuroblastoma, Eur J Cancer, 33: 1430-1437, 1997. 
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with neuroblastoma. Specifically, the 5-year event-free survival for 12- to 18-month old 
children was more than 70-92% compared to 31-38% for older children (27,28,29). 
1.1.3.3 MYCN amplification as a prognostic indicator 
The oncogene MYCN located on chromosome 2p23-24 was first identified in 
neuroblastomas (30), but is also amplified and overexpressed in other tumors including 
retinoblastoma (31) and small-cell lung cancer (32). MYCN amplification is associated 
with advanced stage neuroblastoma and rapid disease progression. Although the precise 
molecular reasons for the association between MYCN amplification and poor  prognosis 
have not been determined, some of the MYCN target genes are involved in cell growth 
and cell cycle progression (33). Cells overexpressing MYCN have shortened cell cycle 
times (34). MYCN overexpression is also associated with increased metastatic potential 
via reduced attachment to extracellular matrix (35). 
Normally MYCN is expressed in the developing nervous system. N-Myc, the 
protein product of the MYCN gene, localizes to the nucleus. N-Myc recognizes E-box 
motifs in the promoter region of target genes and activates transcription (33,36). N-Myc 
target genes include several ABC transporters which efflux many of the drugs used in 
neuroblastoma therapy (reviewed in section 1.3).  
Norris and colleagues evaluated the relationship between several prognostic 
indicators in neuroblastoma and outcome, including MYCN amplification, age, tumor 
stage, and MRP1 expression (10). High MRP1 mRNA expression was the prognostic 
indicator most closely associated with outcome. In particular, high MRP1 levels predicted 
reduced event-free and overall survival in children with neuroblastoma. After adjusting 
outcome for MYCN amplification in multivariate analysis, MRP1 expression remained an 
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independent predictor of survival. Due to the prominence of MYCN amplification in 
neuroblastoma and the molecular relationship between N-Myc and ABC transporter 
expression, the association between MYCN amplification and poor prognosis may be due 
to reduced intracellular accumulation of drugs. 
1.1.3.4 Shimada Histology as a prognostic indicator 
The histopathologic features of neuroblastoma can also be used as prognostic 
indicators. Neuroblastoma histopathology consists of diffuse neuroblastic cell clusters 
with irregular fibrovascular separations. The Shimada histology classification system was 
proposed upon retrospective evaluation of untreated primary neuroblastoma specimens 
from 295 patients for whom at least 2 years of follow-up data were available (37). This 
system includes evaluation of stromal development and neuroblastic cell maturation/ 
differentiation. Initially specimens are classified as stroma-rich or stroma-poor. Stroma-
rich tumors are divided into 3 subgroups: well-differentiated, intermixed, and nodular. 
Both well-differentiated and intermixed tumors are classified as favorable (37,38,39). 
Lastly, a nodular appearance confers unfavorable histology. Favorable or unfavorable 
histology in stroma-poor cases depends on neuroblast differentiation, mitosis-
karyorrhexis index (MKI), and age at diagnosis. 
1.1.3.5 DNA Index 
DNA Index is another feature of neuroblastoma used in risk group stratification to 
guide therapy for children with neuroblastoma. DNA Index (also called DNA ploidy) is a 
measure of tumor DNA content, which is measured by FACS analysis of propidium 
iodide stained nuclei. Aneuploidy is considered a favorable clinical prognostic factor in 
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neuroblastoma. Patients with diploid or tetraploid tumors have a poor prognosis in 
comparison to those with triploid tumors (40,41,42,43).  
1.1.3.6 Risk group stratification 
Heterogeneity is a hallmark of neuroblastoma as demonstrated by variations in 
age at diagnosis, DNA index, tumor histopathology, MYCN amplification, and other 
biological features in neuroblastoma. Based on the heterogeneous survival rates for 
children diagnosed with neuroblastoma, the Pediatric Oncology Group (POG) and 
Children’s Cancer Group designed a risk stratification system to guide risk-related 
therapy based upon prognosis (2). Stratification is based on five prognostic factors: INSS 
stage, age at diagnosis, MYCN status, Shimada histology, and DNA index (Table 1.1). 
This system stratifies children diagnosed with neuroblastoma into three risk groups: low, 
intermediate, and high-risk disease.  
1.1.4 Risk-adapted therapy 
1.1.4.1 Low risk patients 
Patients with low risk disease have greater than 95% predicted event-free survival 
(2,44). Low risk neuroblastoma includes all patients with Stage 1 (localized) disease. 
Localized disease is present in approximately 40% of neuroblastoma cases. In addition, 
all children with Stage 2 disease are classified as low risk except those older than 1 yr 
with MYCN amplification and unfavorable histology. In a POG study of 101 children 
with localized low risk disease treated with surgery as the sole treatment modality, only 9 
patients relapsed (44). Therefore, children with low risk localized disease should undergo 
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surgical resection of the tumor. However, if local recurrence of the tumor is observed, 
these patients can be treated with further surgery or chemotherapy. 
1.1.4.2 Intermediate risk patients 
Patients with intermediate risk disease have a 3-year predicted event-free survival 
greater than 85% (2). Children with intermediate risk disease are stratified according to 
Table 1.1. Therapy for intermediate risk disease includes surgery and chemotherapy. 
Despite the favorable outcome for most patients with intermediate risk neuroblastoma, 
advancements must be made in therapy to reduce acute and long-term toxicities. 
1.1.4.3 High-risk patients 
The focus of this dissertation will remain on the contribution of ABC transporters 
to camptothecin analog resistance in high-risk neuroblastoma. Children diagnosed with 
high-risk neuroblastoma have less than 30% predicted event-free survival. Children with 
high-risk disease are stratified according to Table 1.1. Currently children diagnosed with 
high-risk neuroblastoma receive multiple modalities of therapy including cytotoxic 
chemotherapy, surgery, radiation, and bone marrow transplant. 
The current protocol approach to high-risk neuroblastoma therapy includes 
induction, continuation, and maintenance phases. The goal of induction is to reduce the 
tumor mass by combining agents such as cisplatin, doxorubicin, etoposide, vincristine, 
and cyclophosphamide (45). These five drugs are combined to take advantage of different 
mechanisms of action and non-overlapping toxicities. Moreover, in accordance with the 
Goldie-Coldman hypothesis, the risk of developing drug resistance is decreased by the 
use of non-cross-resistant chemotherapeutic agents to achieve rapid cytoreduction (46). 
In the second phase patients may receive continuation therapy that includes the same 
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agents used during induction. Alternatively, a myeloablative preparative regimen (e.g., 
melphalan, etoposide, and carboplatin or melphalan and total body irradiation) followed 
by autologous stem cell transplantation (47,48) can be used to eradicate residual disease.  
Due to the high relapse rate in children with high-risk neuroblastoma, the goal of 
maintenance therapy is to eliminate minimal residual disease. Currently the 
differentiation inducing agent 13-cis-retinoic acid (isotretinoin) is used in maintenance 
therapy for high-risk neuroblastoma (48).  
Due to the extremely poor outcome in children diagnosed with high-risk 
neuroblastoma, several approaches to improving therapy have been investigated recently 
or are currently in development. New therapeutic modalities such as 131I-MIBG 
(norepinephrine analog that concentrates in sympathetic tissue) or anti-GD2 (antigen 
highly expressed in neuroectodermal tumors) antibodies are under investigation. For 
drugs with wide variability in pharmacokinetics such as topotecan, approaches to 
minimize interindividual variability or to achieve the putatively effective systemic 
exposure have been evaluated.  For example, the pharmacokinetically guided approach to 
topotecan dosing in children with high-risk neuroblastoma showed an excellent response 
to single agent topotecan targeted to the putatively effective systemic exposure (49,15). 
However, chemotherapeutic agents are rarely used as single agents. Due to the favorable 
outcome in some children with neuroblastoma, pharmacokinetically guided topotecan has 
also been evaluated in combination with other drugs active in neuroblastoma such as 
cyclophosphamide.  
Despite the extremely favorable response to topotecan in children with high-risk 
neuroblastoma (60% response rate), the lack of a response in 40% of the children treated 
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with pharmacokinetically guided topotecan indicates clinical resistance to topotecan in 
neuroblastoma (15). The mechanisms for this resistance are not completely understood. 
Identifying the molecular determinants of resistance in children with either intrinsic 
resistance at therapy initiation or acquired resistance after several cycles of chemotherapy 
may help to guide selection of the most active treatment regimens for individual patients. 
Resistance in neuroblastoma is likely to be a multifactorial phenomenon. For the 
camptothecin analogs, mutations in drug target (i.e., topoisomerase I) can lead to 
resistance (50,51). In addition, resistance can be caused by increased intracellular 
detoxification and alterations in cell death or survival pathways. Finally, ABC 
transporters that efflux camptothecin analogs can confer resistance.  
The studies of ABC transporters in neuroblastoma have generated controversial 
and conflicting results. High levels of MRP1 mRNA expression in primary, untreated 
neuroblastoma are associated with reduced survival and event-free survival in patients 
with neuroblastoma (10). Moreover, in tumors without MYCN amplification, high levels 
of MDR1 mRNA expression are associated with poor cumulative survival and event-free 
survival (11). However, the prognostic significance of P-glycoprotein expression, which 
is encoded by MDR1, in neuroblastoma remains controversial (52). For example, de 
Cremoux and colleagues have demonstrated that high levels of  MRP1 or MDR1 did not 
predict neuroblastoma response in a study of biopsy samples from 29 high-risk patients 
(53). In contrast Norris and colleagues have demonstrated that MRP1 is a significant, 
independent predictor of poor prognosis in a prospective analysis of a large group of 
children with neuroblastoma (10). Despite the controversial results of studies of the 
relation between ABC transporter expression in neuroblastoma and clinical outcome, the 
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drugs that are subject to ABC transporter-mediated resistance are used in the treatment of 
neuroblastoma. For example, the camptothecin analogs topotecan and irinotecan have 
anti-tumor activity in children with neuroblastoma, but these drugs are substrates for 
several of the ABC transporters. Elucidation of the role of ABC transporters in resistance 
of primary tumors to topotecan and irinotecan may improve our ability to obtain the 
maximum therapeutic benefit of topotecan and irinotecan in treating neuroblastoma  
1.2 Camptothecin analogs are topoisomerase I interactive agents 
Camptothecin is a naturally occurring alkaloid isolated from the Camptotheca 
acuminata tree (54). Despite demonstrated anti-tumor activity, the clinical utility of 
camptothecin sodium is limited due to severe toxicity, including hemorrhagic cystitis 
characterized by necrotic ulcerations throughout the urinary tract (55,56,57). Other 
toxicities associated with camptothecin sodium include nausea, vomiting, alopecia, 
stomatitis, and diarrhea. The dose limiting toxicity (DLT) of camptothecin sodium is 
myelosuppression, including neutropenia and thrombocytopenia. However, due to the 
promising anti-tumor properties of camptothecin sodium and the pH dependent toxicity 
in the urinary bladder, more water-soluble camptothecin analogs topotecan and irinotecan 
were synthesized. Results of early clinical trials with these compounds demonstrated a 
more acceptable toxicity profile and retention of the promising anti-tumor activity of the 
parent compound. Figure 1.1 shows chemical structures of the parent pentacyclic 
camptothecin as well as topotecan, irinotecan, and SN-38 (the active metabolite of the 
prodrug irinotecan). The clinical utility of both topotecan and irinotecan has been 
demonstrated in pre-clinical and clinical studies of several pediatric tumor models, 
including neuroblastoma.  
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Figure 1.1 Camptothecin analog chemical structure. 
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Camptothecin analogs undergo reversible pH-dependent conversion between the open-
ring carboxylate form and closed-ring lactone form.  At physiologic pH (7.4) the 
carboxylate form of the camptothecin analog predominates; whereas, the lactone form 
predominates under acidic conditions.  The camptothecin analog lactone form is 
responsible for the pharmacological activity at the site of action by interacting with the 
target enzyme topoisomerase I. 
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Topoisomerase I is the molecular target of camptothecin analogs. Topoisomerase 
I relieves torsional strain in DNA by cleaving of a single DNA strand, permitting the 
second DNA strand to pass through the break, and then religating the cleaved strand. 
Camptothecin analogs stabilize these transient DNA-topoisomerase I complexes during 
DNA synthesis. The replication fork arrests upon collision with the resultant covalent 
DNA-topoisomerase I complexes, which are thought to generate lethal DNA strand 
breaks (58). 
At physiological pH the α-hydroxylactone E-ring ring system undergoes 
reversible hydrolysis to form the anionic carboxylic acid moiety (58). In vitro studies of 
camptothecin analogs have demonstrated that the pharmacologically active form is the 
closed ring lactone form (59). The open E-ring carboxylate conformation has little if any 
cytotoxic effect (60). Because the lactone form of camptothecin analogs is considered the 
active conformer, phase I and II trials in children have extensively investigated the 
pharmacokinetics of topotecan lactone and irinotecan/SN-38 lactone.  
1.2.1  Topotecan 
Topotecan (9-dimethylaminomethyl-10hydroxycamptothecin, Hycamtin®) is 
FDA-approved for treatment of ovarian cancer and small cell lung cancer in adults. 
Preclinical xenograft studies in mice have demonstrated activity of protracted topotecan 
administration for treatment of several pediatric solid tumors including neuroblastoma, 
medulloblastoma, glioblastoma, and rhabdomyosarcoma (61,62). Importantly, a steep 
topotecan lactone systemic exposure- response relationship has been documented. 
Zamboni and colleagues investigated the relationship between topotecan systemic 
exposure and response in a panel of six neuroblastoma xenograft models (61). Mice 
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bearing subcutaneous neuroblastoma xenografts were treated with a range of topotecan 
dosages (0.36 to 2 mg/kg) daily for 5 days for 2 weeks [(dx5)2] every 21 days for 3 
courses. The investigators determined the topotecan lactone systemic exposure associated 
with response in a panel of six neuroblastoma xenografts (i.e., NB1382.2, NB1643, 
NB1691, NB1771, NBEB, and NBSD). Four of the 6 neuroblastoma xenograft models 
demonstrated a complete response to topotecan dosages associated with a topotecan 
lactone area under the concentration-time curve (AUC) less than or equal to 88 
ng/mL*hr. Both in vivo and in vitro NB1643 was relatively sensitive to topotecan; 
whereas, NB1691 required a topotecan lactone systemic exposure of 290 ng/mL*hr to 
achieve a complete response (63). Despite the resistance of NB1691 to topotecan both in 
vitro and in vivo, the favorable response of four other neuroblastoma xenograft models to 
topotecan provided a strong basis for further study of topotecan in neuroblastoma clinical 
trials. 
Several topotecan dosage schedules have been evaluated in phase I and II clinical 
trials in children. A 72 hr continuous topotecan infusion showed minimal anti-tumor 
activity in neuroblastoma (Table 1.3). A five-day schedule of topotecan was minimally 
active in neuroblastoma, but interindividual variability in topotecan pharmacokinetics 
was high (66, 67). 
However, topotecan is an S-phase selective agent. Maximizing drug exposure to 
cells (particularly those with long cell-cycle times and low growth fractions) in S-phase 
can be achieved using protracted administration schedules such as daily for five days for 
two to three weeks (68). Studies of topotecan in xenograft models demonstrated the 
superiority of protracted schedules of administration over high doses administered
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Table 1.3 Topotecan clinical trials in children with recurrent or refractory solid 
tumors including neuroblastoma. 
 
Phase Dosage N 
(n with 
NB) 
MTD 
(mg/m2/d) 
DLT Responses 
in children 
with NB 
Notes Ref. 
I 72 hr CI 27 (9) 1.0 
with G-
CSF 
 
Myelosuppression 1 CR at 1.3 
mg/m2/day 
maintained 
for 8 
months; 5 
SD 
 (64) 
II 72 hr CI 93 (not 
reported) 
1.3 Myelosuppression 1 CR  Schedule 
inactive 
in 
recurrent/ 
refractory 
NB 
(65) 
I Dx5 
Q 21d 
30 min 
i.v. 
infusion 
40 (9) 1.4 
without 
G-CSF; 
2.0 
with G-
CSF 
 
Neutropenia, 
thrombocytopenia 
3 PR  7-fold 
range in 
topotecan 
lactone 
systemic 
clearance 
(66) 
II Dx5 Q 
21d by 
30 min 
i.v. 
infusion 
20 (13) 1.48 
 
Anemia, 
neutropenia, 
thrombocytopenia 
2 PR; 4 SD   (67) 
 
Abbreviations: NB- neuroblastoma, MTD- maximum tolerated dose, DLT- dose limiting 
toxicity, CI- continuous infusion, G-CSF- granulocyte colony stimulating factor, CR- 
complete response, Dx5 Q 21 d- daily for 5 days every 21 days, PR- partial response, SD- 
stable disease 
 
Sources:  Pratt CB, et al. Phase I study of topotecan for pediatric patients with malignant 
solid tumors, J Clin Oncol, 12: 539-543, 1994. 
 
Blaney SM, et al. Phase II trial of topotecan administered as 72-hour continuous infusion 
in children with refractory solid tumors: a collaborative Pediatric Branch, National 
Cancer Institute, and Children's Cancer Group Study, Clin Cancer Res, 4: 357-360, 1998. 
 
Tubergen DG, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) 
study of topotecan using a five-day course in children with refractory solid tumors: A 
Pediatric Oncology Group Study, J Ped Hem/Onc, 18: 352-361, 1996. 
 
Langler A, et al. Topotecan in the treatment of refractory neuroblastoma and other 
malignant tumors in childhood - a phase-II-study, Klin Padiatr, 214: 153-156, 2002. 
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Intermittently (68). Based on the strength of these preclinical data, Santana and 
colleagues evaluated the protracted administration with pharmacokinetically guided 
dosing of topotecan to minimize variability in systemic exposure and achieve the 
putatively effective topotecan systemic exposure in children. 
Santana and colleagues conducted a pilot study of protracted topotecan in children 
with refractory solid tumors (Table 1.4) (49). Due to the wide interpatient variability in 
topotecan pharmacokinetics and the documented relationship between topotecan systemic 
exposure and response, the investigators used a pharmacokinetically guided dosing 
approach to minimize interpatient variation in topotecan systemic exposure. This 
approach also removes interindividual variability as a factor contributing to resistance. 
The single day topotecan lactone systemic exposure evaluated in children was based upon 
anti-tumor response in xenograft models at topotecan lactone AUC ranging from 88 to 
144 ng/mL*hr (68,66,61). 
In the pilot Phase I trial the pharmacokinetically guided dosing resulted in 
achieving the targeted systemic exposure in 78% (46 of 59) of the pharmacokinetic 
studies (49). The investigators also demonstrated a significant reduction in AUC values 
outside of the targeted range in comparison to that which would be achieved using a fixed 
dosing approach based solely on body surface area. Due to the manageable toxicity and 
favorable responses to pharmacokinetically guided dosing of protracted topotecan, a 
prospective phase II trial was conducted in previously untreated high-risk neuroblastoma 
(Table 1.4) (15). The pharmacokinetic targeting success rate was 72%, indicating the 
superiority of this individualized approach to topotecan dosing over fixed dosing to 
achieve a desired AUC. 
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Table 1.4 Clinical trials of topotecan pharmacokinetically guided dosing in 
children with solid tumors including neuroblastoma. 
 
Phase Dosage 
Schedule 
N (n 
with 
NB) 
Population Single Day 
Topotecan 
Lactone 
Target 
(ng/mL*hr)
NB 
Responses 
Reference
I (Dx5)2 
Q 24-28 d  
30 min 
i.v. infusion 
15 (5) Recurrent/ 
refractory 
solid tumors 
Cohort 1: 
120-160 
Cohort 2: 
80-120 
Cohort 1: 
1 PR  
Cohort 2: 
1 PR 
(49) 
II (Dx5)2 
Q 28 d  
30 min 
i.v. infusion 
30 (30) Previously 
untreated 
high-risk NB 
80-120 1 CR 
17 PR 
(15) 
 
Abbreviations:  NB- neuroblastoma, (Dx5)2- daily for 5 days for 2 weeks, Q 24-28 d- 
every 24 to 28 days, i.v.- intravenous, Q 28 d, every 28 days, PR- partial response, CR- 
complete response 
 
Sources:  Santana VM, et al. A pilot study of protracted topotecan dosing using a 
pharmacokinetically guided dosing approach in children with solid tumors, Clin Cancer 
Res, 9: 633-640, 2003. 
 
Santana VM, et al. Improved response in high-risk neuroblastoma with protracted 
topotecan administration using a pharmacokinetically guided dosing approach, J Clin 
Oncol, 23: 4039-4047, 2005. 
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The feasibility of pharmacokinetically guided topotecan dosing determined in the 
pilot study was confirmed in this phase II study. The 60% response rate (complete and 
partial responses) was excellent in these previously untreated patients, especially in 
comparison to studies in relapse patients where the response rate was only 15% (67). The 
60% response rate to pharmacokinetically guided topotecan was also more favorable than 
the 40% response rate observed in a Phase II POG study of topotecan (2 mg/kg 
administered dx5) in 33 children with previously untreated Stage IV neuroblastoma (3). 
The higher response rate in the Santana study might be due to several factors including 
number of days of topotecan, dosage of topotecan, and systemic exposure of topotecan. 
The patients with refractory tumors on the Langler study (67) might represent a more 
drug resistant disease subset than the previously untreated population in the Santana 
study. In the Langler and POG (3) studies, patients received only 5 days of topotecan 
rather than 10 days over 2 weeks. Moreover, the daily topotecan dosages were lower in 
the Langler and (median 1.48, range 0.4-1.7 mg/m2) and POG studies (2 mg/m2) than in 
the Santana study (median 2.7, range 0.95-3.8 mg/m2). However, since topotecan 
pharmacokinetics were not reported in the Langler or POG studies, direct comparison of 
topotecan pharmacokinetics cannot be made to those reported by Santana and colleagues. 
Based on the documented interindividual variability in topotecan pharmacokinetics, 
substantial variation in topotecan systemic exposure was likely present in the studies 
using a fixed dosing approach. The approach to topotecan fixed dosing for 5 days every 
21 days without dosage adjustment based on a targeted systemic exposure is probably 
subtherapeutic, especially in comparison to the protracted topotecan schedule targeting a 
systemic exposure of 80-120 ng/mL*hr. Based on the systemic exposure-response 
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relationship, interindividual variability in drug exposure likely contributes to some cases 
of apparent topotecan resistance. However, the pharmacokinetic guided topotecan dosing 
approach minimizes interindividual variability in topotecan systemic exposure. 
Although protracted topotecan with pharmacokinetically guided dosing 
adjustments to achieve an AUC of 80-120 ng/mL*hr resulted in an excellent response 
rate in chemotherapy naïve children diagnosed with neuroblastoma, the tumor response 
rate (60%) was lower than the pharmacokinetic targeting success (72%). The patients 
who did not respond to pharmacokinetically guided protracted topotecan represent a 
subset of the disease that is clinically resistant to topotecan.  
Resistance to topotecan can be multifactorial. Reduced expression of 
topoisomerase I, the molecular target of topotecan, can result in topotecan resistance. 
Topoisomerase I mutations that affect topotecan binding may confer topotecan resistance 
(50,51). Increased DNA repair via tyrosyl-DNA-phosphodiesterase overexpression  can 
also lead to camptothecin analog resistance(69). Finally, ABC transporter-mediated 
efflux from the cell may result in topotecan resistance. 
1.2.2 Irinotecan 
Irinotecan (7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin, 
Camptosar®), a camptothecin analog, has been evaluated in a variety of pediatric tumors, 
including neuroblastoma. The prodrug irinotecan has been FDA approved for treatment 
of metastatic colorectal cancer. Irinotecan is metabolized by carboxylesterases to the 
active metabolite SN-38. Preclinical and clinical studies have demonstrated that i.v. 
irinotecan was also active against pediatric tumors including rhabdomyosarcoma, 
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medulloblastoma, glioblastoma, and neuroblastoma (62,70). Oral irinotecan was active in 
a panel of six neuroblastoma xenograft models (71). 
Vassal and colleagues demonstrated irinotecan activity in a panel of three 
neuroblastoma xenografts established from patients with poor prognosis (72). IGR-N835 
was established from a previously treated patient with MYCN amplified stage IV disease 
lacking MDR1 expression. IGR-NB3 and IGR-NB8 were derived from two patients with 
untreated stage III disease, MYCN amplification, and MDR1 overexpression, each of 
which was refractory to chemotherapy. A complete or partial response to irinotecan 
(either using a dx5 or q4dx5 administration schedule) was achieved in all 3 xenograft 
models studied. Although several investigators have demonstrated resistance to irinotecan 
and SN-38 in Pgp overexpressing cell lines in vitro (73,74), the response to irinotecan of 
xenografts overexpressing Pgp suggests that Pgp did not play a major role in irinotecan 
resistance in this model. However, to confirm this hypothesis it would be necessary to 
demonstrate irinotecan efficacy in patients with neuroblastoma that overexpresses Pgp. 
In contrast to the dx5 irinotecan dosing approach reported by Vassal et al, 
Thompson and colleagues demonstrated the anti-tumor activity of protracted (i.e., daily 
for 5 days for 2 weeks) i.v. irinotecan in a panel of 6 neuroblastoma xenografts (70). The 
characteristics of each xenograft model are listed in Table 1.5. A single course of 
irinotecan 10 mg/kg daily for 5 days for 2 weeks induced a complete response in 
NB1691, NB1643, NBEB, and NB1382.2 tumors. Also, a partial response was achieved 
in NB1771. However, NBSD, which was derived from a bone marrow aspirate, did not 
respond significantly to this irinotecan dosage. This might indicate that neuroblastoma 
bone marrow metastases are more refractory to irinotecan than the primary tumor. The
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Table 1.5 Neuroblastoma xenograft features. 
 
Xenograft Stage Site Prior Therapy MYCN 
Amplification
NB1691 D Adrenal AraC, Dauno, 6-TG, VP-16, 
5-azacytidine 
Yes 
NB1643 D Retro-peritoneal None Yes 
NB1382.2 C Retro-peritoneal VCR, VP-16, CTX, CDDP, 
carboplatin 
Yes 
NB1771 D Adrenal None Yes 
NBSD D Bone marrow 
aspirate 
CTX, Dox, CDDP, VM-26 Yes 
NBEB D Adrenal CTX, Dox,CDDP,VM-26 No 
 
Abbreviations:  AraC- cytosine arabinoside, Dauno- daunorubicin, 6-TG- 6-thioguanine, 
VP-16- etoposide, VCR- vincristine, CTX- cyclophosphamide, CDDP- cisplatin, Dox- 
doxorubicin, VM-26- teniposide. (Note: stage D is equivalent to current INSS stage 4.) 
 
Source:  Thompson J, et al. Efficacy of systemic administration of irinotecan against 
neuroblastoma xenografts, Clin Cancer Res, 3: 423-431, 1997. 
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 investigators also determined that the irinotecan and SN-38 systemic exposures 
associated with the minimum effective dose in xenograft models can also be achieved 
clinically in children with cancer (17). Furthermore, at systemic exposures tolerated in 
children (75) oral irinotecan elicited anti-tumor responses in the same panel of 
neuroblastoma xenografts (71). 
Several schedules of irinotecan administration have been evaluated in children 
with solid tumors in phase I trials (Table 1.6). The major toxicities associated with 
irinotecan were myelosuppression and diarrhea. Favorable responses were observed in 
several tumor types, for neuroblastoma in particular. Based solely on the phase I clinical 
data, the optimal irinotecan schedule cannot be determined unequivocally. However, the 
extensive preclinical studies of Houghton and colleagues have demonstrated the 
superiority of protracted irinotecan to shorter schedules. Moreover, due to the potential 
for failure to respond to irinotecan, future clinical trials of irinotecan should include 
prospective evaluation of factors that might influence anti-tumor response, including 
expression of ABC transporters in the tumor. 
1.3 ABC transporters 
The human ABC superfamily of transmembrane proteins contains 49 genes 
divided into 7 subfamilies (ABCA through ABCG)  based upon gene structure, order of 
domains, and amino acid sequence homology (79). ABC transporters are expressed in 
both normal and tumor tissues and efflux a variety of endogenous substrates and 
xenobiotics from cells against a concentration gradient. ABC transporters expressed in 
normal tissues protect cells from toxic substances. ABC transporters expressed in normal 
tissues also play a role in the pharmacokinetics (absorption, distribution, metabolism, and 
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Table 1.6 Irinotecan phase I clinical trials in children with recurrent or 
refractory solid tumors including neuroblastoma. 
 
Dosage 
Schedule 
N 
(n with NB) 
MTD, DLT Responses in 
children with 
NB 
Reference 
(Dx5)2 by 1 
hr i.v. 
infusion 
23 (5) 20 mg/m2/day, diarrhea 1 PR (17) 
Dx5 q 21 d 
by 1 hr i.v. 
infusion 
35 (7) Heavily pretreated 
stratum: 39 mg/m2/day, 
neutropenia/ 
thrombocytopenia; 
Less heavily pretreated 
stratum: 50 mg/m2/day, 
diarrhea 
1 PR, 1 SD (76) 
 QW for 3W 
by 1 or 2 hr 
i.v. infusion 
Less heavily 
pretreated: 
48 (5) 
More heavily 
pretreated: 
33 (11) 
600 mg/m2/dose, delayed 
diarrhea and cholinergic 
syndrome for less 
heavily pretreated; 
neutropenia for heavily 
pretreated 
1 PR 
persisted for 
5 courses 
(77) 
Dx3 by 2 hr 
i.v. infusion 
q 28d 
28 (26) 160-180 mg/m2/day, 
myelosuppression 
(hematopoietic lineages) 
and diarrhea 
4 PR (78) 
 
Abbreviations: NB- neuroblastoma, MTD- maximum tolerated dose, DLT- dose limiting 
toxicity, (Dx5)2- daily for 5 days for 2 weeks, Dx5 q 21 d- daily for 5 days every 21 
days, QW- every week, 3W- 3 weeks, PR- partial response, SD- stable disease 
 
Sources:  Furman WL, et al. Direct translation of a protracted irinotecan schedule from a 
xenograft model to a phase I trial in children, J Clin Oncol, 17: 1815-1824, 1999. 
 
Blaney S, et al. A phase I study of irinotecan in pediatric patients: a pediatric oncology 
group study, Clin Cancer Res, 7: 32-37, 2001. 
 
Vassal G, et al. A phase I study of irinotecan as a 3-week schedule in children with 
refractory or recurrent solid tumors, J Clin Oncol, 21: 3844-3852, 2003. 
 
Mugishima H, et al. Phase I study of irinotecan in pediatric patients with malignant solid 
tumors, J Pediatr Hematol Oncol, 24: 94-100, 2002. 
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excretion) of drugs that are ABC transporter substrates. Finally, multi-drug resistance via 
drug efflux is one of the functional consequences of ABC transporter expression in 
malignant cells. 
ATP binding or hydrolysis drives this efflux process. Several mechanisms for 
extruding substrates from a cell have been proposed, including those of a classical pump, 
a flippase, a hydrophobic vacuum cleaner, and an ATP switch. According to the classical 
pump model, ABC transporters remove substrates directly from the cytoplasm to the 
extracellular space. However, because substrates have been shown to enter the transporter 
via the membrane and not the cytoplasm, ABC transporters likely function according to 
an alternate mechanism (80). According to the flippase model, a transporter flips a 
substrate from the inner membrane leaflet to the outer membrane leaflet from which the 
substrate could diffuse into the extracellular environment (81). The hydrophobic vacuum 
cleaner model proposes that the transmembrane domains associate to form a channel in 
the plasma membrane (82). Upon passive diffusion of a substrate into the lipid bilayer, 
the transporters detect substrates in the membrane and efflux them from the cell. The 
ATP switch model is similar to the hydrophobic vacuum cleaner model. Upon substrate 
binding to a high-affinity site on the transmembrane domain (TMD) of the inner 
membrane leaflet, two ATP molecules bind the nucleotide binding domain (NBD), 
inducing a conformational change in the TMD (83). This conformational change exposes 
the substrate to the extracellular space, and the affinity of the transporter for the substrate 
is reduced. Hence, the bound drug is released into the extracellular space. Following ATP 
hydrolysis, inorganic phosphate and ADP are released, and the transporter is restored to 
its basal conformation. 
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In addition to similar mechanisms of action, ABC transporters share structural 
features. Structural domains common to this protein superfamily include a TMD and a 
highly conserved ATP-binding cassette, which is also called the nucleotide binding 
domain (NBD).  The ATP-binding domains known as Walker A and Walker B motifs in 
the NBD are separated by 90-120 amino acids (79). A functional transporter is comprised 
of at least 2 TMDs, each of which contains 6-11 membrane spanning α-helices.  
The ABC transporters Pgp, MRP1, MRP2, MRP4, and BCRP may play a role in 
resistance to topotecan, irinotecan, and SN-38. The role of these transporters in resistance 
to topotecan, irinotecan, and SN-38 in addition to what is known about their expression in 
neuroblastoma will be summarized below. 
1.3.1 P-glycoprotein 
P-glycoprotein (Pgp) was the first member of the ABC transporter superfamily 
described(84), and it is encoded in humans by the gene ABCB1, also known as MDR1. 
The protein product of the MDR1 gene is a 170 kDa plasma membrane glycoprotein. Pgp 
has also been shown to be expressed in the membranes of organelles such as the nuclear 
envelope and Golgi apparatus (85,86). Although the full-length MDR1 gene was not 
cloned until 1986 (87), Pgp expression in multi-drug resistant cell lines was first 
demonstrated in 1976 (84). 
Immunohistochemical analysis has demonstrated Pgp expression in various 
human tissues. Pgp was expressed in the epithelium of the gastrointestinal tract and 
bronchus, and in vascular endothelium, notably in the blood-brain barrier. Pgp was also 
expressed in secretory and excretory tissues including bile canaliculi and ductules, renal 
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tubules, pancreatic ducts, mammary glands, prostate glands, salivary glands, and adrenal 
glands (88). 
1.3.1.1 Pgp substrates 
Pgp substrates include a wide variety of structurally diverse, hydrophobic 
xenobiotics including anthracyclines, anthracenes, vinca alkaloids, epipodophyllotoxins, 
tubulin polymerizing drugs, HIV-1 protease inhibitors, and fluorophores. Pgp substrates 
used in neuroblastoma therapy include doxorubicin, vincristine, etoposide, and teniposide 
(18). In addition, the camptothecin analogs topotecan and irinotecan, which are 
components of neuroblastoma therapy, have been evaluated as Pgp substrates with 
conflicting results (73,89,90).  
The first studies demonstrating that Pgp confers resistance to topotecan were 
conducted in drug selected cell lines. Chinese hamster ovary cells selected for colchicine 
resistance (CHRC5) that overexpressed Pgp were 15 times more resistant to topotecan 
than the parental cell line (AuxB1) and 10 times more resistant to SN-38 (89,73). 
Topotecan and SN-38 accumulation and drug-stabilized topoisomerase I- DNA 
complexes were reduced in CHRC5 compared to AuxB1, suggesting reduced intracellular 
topotecan or SN-38 in CHRC5 due to Pgp-mediated efflux. However, these were drug 
selected cell lines, and expression of other transporters that might confer topotecan 
resistance (e.g., BCRP or MRP1) cannot be ruled out. These studies were performed prior 
to identification of other drug transporters; hence, the contribution of other ABC 
transporter families to the results of these studies is unknown. 
In contrast to the drug selected cell lines used by Hendricks (89) and Mattern et al 
(73), Jansen and colleagues demonstrated irinotecan and SN-38 resistance in cells 
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transfected with MDR1 cDNA (74). A melanoma cell line transfected with MDR1 was 5 
times more resistant than the parental cell line to irinotecan and only 1.4 times as resistant 
to SN-38. When these same cell lines were implanted as xenografts in mice, virtually no 
difference was observed in sensitivity to irinotecan, indicating that the in vitro and in vivo 
model systems were not equivalent. Specifically, the xenografts had higher 
topoisomerase I activity than the cell lines in vitro, which may account for the lack of 
resistance observed in vivo. Similar to the results of Mattern and colleagues, the in vitro 
level of resistance to topotecan and SN-38 was one to two orders of magnitude lower 
than for the classical Pgp substrates doxorubicin and vincristine. 
Pommier and colleagues used two in vitro systems to demonstrate that Pgp 
confers resistance to topotecan (90). First, KB-V1, a human carcinoma cell line selected 
for vinblastine resistance, was more resistant to camptothecin, topotecan, and SN-38 than 
the parental KB-3-1 cell line. In addition to the vinblastine selected cell line, 
camptothecin analog cytotoxicity was studied in an isogenic system, NIH3T3 and NIH-
MDR-G185. The resistant cell line was transfected with a plasmid encoding Pgp and 
maintained in colchicine. NIH-MDR-G185 showed increased resistance to topotecan, but 
not camptothecin or SN-38. The investigators did, however, make the important 
distinction that even though Pgp confers resistance to topotecan, Pgp confers a much 
higher level of resistance to drugs such as doxorubicin. 
1.3.1.2 Pgp expression in neuroblastoma 
Multidrug resistance conferred by ABC transporters can be either intrinsic or 
acquired. Intrinsic resistance of an untreated tumor can be due to expression of ABC 
transporters. Acquired resistance refers to chemotherapeutic selection of drug resistant 
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clones (e.g., those expressing ABC transporters). Intrinsic and acquired resistance has 
been studied in neuroblastoma, and both may have implications for clinical outcomes 
including response and survival. 
Pgp is expressed in many tumor types, especially those that arise from tissues that 
normally express Pgp. Using three monoclonal antibodies to different Pgp epitopes, Pgp 
expression has been demonstrated prior to chemotherapy in non-Hodgkin’s lymphoma, 
intestinal leiomyosarcoma, adenocarcinoma of the stomach, colon, kidney, breast, and 
adrenal cortex (88). In addition, Fojo and colleagues demonstrated that MDR1 mRNA is 
expressed in the adrenal gland, adrenal medulla, and in neuroblastoma tumor samples of 
unspecified stage taken from 3 patients following relapse after treatment with vincristine 
and doxorubicin (91). Although the investigators did not evaluate the relationship 
between MDR1 expression and outcome, several other groups have conducted such 
analyses in neuroblastoma. 
Results of studies evaluating the significance of Pgp mRNA or protein expression 
in neuroblastoma are inconsistent (92,93,52,10). The inconsistencies may be explained by 
small study populations, differences in prior therapy, absence of paired samples at 
diagnosis and relapse, failure to isolate tumor tissue from normal tissue, and the potential 
lack of correlation between mRNA and protein expression level (94). The most reliable 
studies using immunohistochemistry to detect protein expression in neuroblastoma 
biopsies have demonstrated that overall survival is significantly lower in children with 
tumors that express Pgp at diagnosis (93) and Pgp expression at diagnosis increases the 
risk of death in neuroblastoma by 60% (52). Therefore Pgp expression in neuroblastoma  
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is likely an unfavorable feature and may confer poor prognosis in neuroblastoma at least 
perhaps in an as yet undefined subset of patients (93,52). 
1.3.2  MRP1 
The human MRP1 (ABCC1) gene contains 31 exons, maps to chromosome 16p13, 
and encodes a 190 kDa protein. MRP1 was first identified in a lung cancer cell line 
selected for doxorubicin resistance without expression of Pgp (95). MRP1 mRNA 
expression was ubiquitous in a panel of human tissues (96,97). In addition, western blot 
and immunohistochemical analysis of normal human tissues demonstrated essentially 
ubiquitous MRP1 expression (98). MRP1 was expressed in the adrenal gland, lung, heart, 
skeletal muscle, liver, spleen, kidney, stomach, small and large intestine, prostate gland, 
testis, ovary, and erythrocytes. However, MRP1 was not observed in endothelium. 
1.3.2.1 MRP1 substrates 
Some overlap exists between Pgp and MRP1 substrates. As for Pgp, MRP1 
transports both endogenous and xenobiotic substrates. MRP1 substrates include 
glutathione S-conjugates, sulfate conjugates, and glucuronides (Table 1.7) (99). In an 
isogenic system Chen and colleagues demonstrated an ATP-dependent reduction in  
intracellular accumulation of both irinotecan and SN-38 in KB-3-1 cells transfected with 
MRP1 cDNA (100). Furthermore, compared to the parental cell line the MRP1 
overexpressing cell line was 7 and 15 times more resistant to irinotecan and SN-38, 
respectively. 
Allen and colleagues knocked out the murine orthologs of human MRP1 and 
MDR1 (Mrp1, Mdr1a, and Mdr1b respectively)  in  murine  embryonic fibroblasts (MEF) 
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 Table 1.7 Partial list of endogenous and xenobiotic MRP1 substrates. 
 
Class Substrate 
Drugs Methotrexate 
 Doxorubicin, daunorubicin, epirubicin, idarubicin 
 Etoposide 
 Vincristine, vinblastine 
 Irinotecan, SN-38, topotecan 
GSH conjugates Doxorubicin-SG 
 Cyclophosphamide-SG 
 Melphalan-SG 
 Leukotriene C4
 PGA2-SG, PGJ2-SG 
Glucuronide conjugates Etoposide-Gluc 
 SN-38-Gluc 
 E217βG 
 Glucuronosylbilirubin 
Sulfate conjugates Estrone-3-sulfate 
 Dehydroepiandrosterone sulfate 
 
Source:  Deeley RG and Cole SP. Substrate recognition and transport by multidrug 
resistance protein 1 (ABCC1), FEBS Lett, 580: 1103-1111, 2006. 
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to examine the contribution of each gene to basal drug resistance to a panel of drugs 
including topotecan and SN-38 (101). In Mdr1a/1b null MEFs, a small (but significant) 
increase was observed in sensitivity to topotecan and SN-38. However, a much larger 
increase in topotecan and SN-38 sensitivity was observed in the triple knockout MEFs 
(Mrp1 and Mdr1a/1b null). Therefore, the camptothecin analogs are better substrates for 
MRP1 than Pgp. 
1.3.2.2 MRP1 expression in neuroblastoma 
Because MRP1 transports multiple drugs used in neuroblastoma therapy including 
the camptothecin analogs, the relationship between MRP1 expression in neuroblastoma 
and outcome has been examined. Norris and colleagues used RT-PCR to determine the 
MRP1 mRNA expression in 60 primary, untreated neuroblastomas (10). Patients who 
received chemotherapy were treated with regimens including the MRP1 substrates 
vincristine and doxorubicin. The cumulative survival rate was higher in patients with low 
MRP1 expression than in those with high expression (94% vs. 57%, respectively, 
P<0.001, log-rank test). The 5-year event-free survival (EFS) rate was also higher in 
patients with low MRP1 expressing tumors than in those with high expression (46% vs. 
91%, respectively). 
The same group confirmed these findings in a large prospective study of 209 
neuroblastoma samples using RT-PCR (12). When all patients were evaluated based upon 
MRP1 expression level, 5-year EFS was significantly higher in patients with low MRP1 
expressing tumors in comparison to high MRP1 expression (76% vs. 40%, P< 0.001, log-
rank test). 
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High MRP1 expression remained a significant predictor of outcome in three 
subsets of patients. First, in patients with localized disease, those with high MRP1 had 
worse EFS than those with low expression (56% vs. 90%, P= 0.001, log-rank test). Next, 
children with MYCN nonamplified tumors and high MRP1 had worse EFS than those 
with low expression (46% vs. 81%, P<0.001, log-rank test). Finally, in children with 
stage 4 disease high MRP1 was associated with extremely poor EFS compared to those 
with low expression (14% vs. 44%, P < 0.001, log-rank test). Therefore, even in patients 
with favorable prognostic features such as localized disease or nonamplified MYCN, 
MRP1 expression may be a useful indicator of prognosis that can be used to guide 
therapy. 
MRP1 mRNA expression is a prominent feature in neuroblastoma and may be a 
strong, independent indicator of poor prognosis. However, due to the essentially 
ubiquitous MRP1 expression in normal tissue, modulation of tumor-specific MRP1-
mediated resistance presents a significant challenge. However, the relationship between 
MRP1 expression in neuroblastoma and poor prognosis may not be solely attributed to 
drug efflux. As MRP1 expression is strongly correlated with MYCN amplification, the 
expression of this ABC transporter may be a surrogate marker for another currently 
unidentified MYCN target gene responsible for poor prognosis. Furthermore, these studies 
have focused on the MRP1 mRNA expression, and therefore the question remains about 
the mechanistic implications of the strong correlation between MYCN amplification and 
MRP1 mRNA expression. It has not yet been determined whether MRP1 and MYCN 
have independent roles in neuroblastoma. A mechanistic explanation for the poor 
prognosis in patients with high MRP1 expression remains to be elucidated.  
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1.3.3 MRP2 
The human ABCC2 gene contains 32 exons (102) mapping to chromosome 10q24 
and encodes a 180 kDa protein with alternative nomenclature that includes cMOAT (for 
canalicular multispecific organic anion transporter) and MRP2 (multidrug resistance 
associated protein 2). The MRP2 protein sequence is 48% homologous to MRP1 (103). 
MRP2 is primarily expressed in the hepatocyte canalicular membrane and mediates the 
hepatobiliary excretion of organic anions including glutathione and bilirubin 
glucuronides (104). MRP2 expression has also been demonstrated at the apical membrane 
of the renal proximal tubules (105).  
1.3.3.1 MRP2 substrates 
As with Pgp and MRP1, there is considerable overlap in substrate specificity 
between MRP1 and MRP2. MRP2 substrates include vincristine, vinblastine, 
methotrexate, cisplatin, doxorubicin, epirubicin, etoposide, cyclophosphamide, 
irinotecan, and SN-38 (106,107,108). MRP2 both transports and confers resistance to 
irinotecan and SN-38. First in the HepG2 hepatic cancer cell line expressing MRP2, 
antisense RNA to MRP2 reduced MRP2 expression and increased sensitivity to both 
irinotecan and SN-38 (106). Chu and colleagues used canalicular membrane vesicles 
isolated from rats to demonstrate the ATP-dependent transport of both the lactone and 
carboxylate forms of SN-38G and the carboxylate forms of irinotecan and SN-38 (109).  
1.3.3.2 MRP2 in neuroblastoma 
To date MRP2 protein expression has not been demonstrated in neuroblastoma. 
Norris and colleagues have demonstrated that MRP2 mRNA levels in patients with 
neuroblastoma did not discriminate between treatment success or failure, but analysis of 
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MRP2 protein expression was not reported (110). However, due to MRP2-mediated 
transport of drugs used in neuroblastoma therapy including irinotecan/SN-38, vincristine, 
cisplatin, and doxorubicin, MRP2 protein expression should be further evaluated in 
neuroblastoma. Although neuroblastoma does not arise from a tissue that normally 
expresses MRP2, expression of MRP2 in neuroblastoma is possible. Due to the potential 
for efflux of irinotecan and SN-38 in MRP2-expressing tumor cells, if MRP2 is expressed 
in neuroblastoma, the relationship between MRP2 expression and response to therapy 
including MRP2 substrates should be explored. 
1.3.4 MRP4 
The human ABCC4 gene maps to chromosome 13q32 (111) and encodes the 170 
kDa protein MRP4 (112). The organic anion transporter MRP4 was first identified in 
1997 by searching the human expressed sequence tag (EST) database for sequences 
homologous to the 3’-ends of MRP1 and MRP2 (113). Human MRP4 mRNA expression 
was demonstrated in lung, kidney, bladder, and gall bladder and in drug resistant cell 
lines derived from several tumor types including non-small cell lung cancer, small cell 
lung cancer, lung adenocarcinoma, and promyelocytic leukemia. Tissue distribution 
studies  have shown that MRP4 is also expressed in the adrenal gland, on the apical side 
of  renal proximal tubules and capillaries in the brain, and the basolateral side of the 
choroid plexus epithelium (114,115,116). 
1.3.4.1 MRP4 substrates 
MRP4 is an organic anion transporter, and its substrates include both xenobiotics 
and endogenous substances. MRP4 was identified as a transporter of the nucleoside 
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analog 9-(2-phosphonylmethoxyethyl) adenine (PMEA) (111). Inverted membrane 
vesicles were used to identify the endogenous MRP4 substrates cGMP, cAMP, and 
estradiol 17-β-D-glucuronide (E217βG) (117). Prostaglandin E1 (PGE1) and PGE2 have 
also been identified as endogenous substrates (118). MRP4 also effluxes 6-
mercaptopurine (6-MP) monophosphates, 6-thioguanine (6-TG) monophosphates, and 
methotrexate (117,119) and confers resistance to cyclophosphamide, but not etoposide, 5-
fluorouracil, carboplatin, vincristine, vinblastine, or paclitaxel (120). 
Topotecan is an MRP4 substrate (114). In particular, increasing topotecan 
concentrations reduced ATP-dependent uptake of E217βG into inverted membrane 
vesicles overexpressing MRP4. Also, Saos2 cells overexpressing MRP4 were 5 times 
more resistant to topotecan and accumulated less topotecan intracellularly than the 
parental cell line.  
Subsequently Tian and colleagues used stably transfected HepG2 (which 
endogenously expresses MRP4 (121)) cells overexpressing MRP4 to demonstrate that 
MRP4 confers resistance to other camptothecin analogs (120). Cells overexpressing 
MRP4 were 3- to 6-fold resistant to irinotecan lactone. MRP4 conferred 8- to 9-fold 
resistance to SN-38 lactone and carboxylate. The level of resistance to SN-38 and 
irinotecan was similar to that observed for the classical MRP4 substrates bis-POM-
PMEA and methotrexate. Furthermore, this increase in resistance to both SN-38 and 
irinotecan was accompanied by a 2- to 4-fold reduction in intracellular accumulation of 
both irinotecan and SN-38.  
Using the same MRP4 overexpressing HepG2 cell line, Tian and colleagues also 
confirmed that MRP4 transports and confers resistance to topotecan (122). MRP4 
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overexpression conferred 12-fold resistance to topotecan. The level of topotecan 
resistance in MRP4 overexpressing cells was similar to that for bis-POM-PMEA. In 
addition, topotecan intracellular accumulation was reduced in the MRP4 overexpressing 
cells. Due to the endogenous MRP4 expression in the HepG2 cell line, these data provide 
information about the contribution of overexpressed MRP4 to camptothecin analog 
transport and resistance. The data do not give information about the level of resistance 
conferred by the basal level of MRP4 expression. To determine the contribution of basal 
MRP4 expression, the gene could be silenced using RNAi. Alternatively, if an inhibitor 
specific for MRP4 (and not other ABC transporters) existed, it could be used to assess the 
contribution of MRP4 to camptothecin analog transport and resistance. 
1.3.4.2 MRP4 in neuroblastoma 
Norris and colleagues reported that MRP4 mRNA expression was correlated with 
MYCN amplification in neuroblastoma and was an independent predictor of poor 
outcome (110). Although MYCN has not yet been shown to activate MRP4 transcription, 
the MRP4 promoter contains an E box. Therefore, MRP4 may be a MYCN target gene. 
In addition, MRP4 may confer clinical resistance to drugs used in neuroblastoma therapy, 
notably the camptothecin analogs. Hence, the contribution of MRP4 expression to 
camptothecin analog resistance in neuroblastoma will be explored in this project. 
1.3.5 BCRP 
The breast cancer resistance protein (BCRP) is the product of the ABCG2 gene 
and maps to chromosome 4q22. BCRP aliases include MXR (for mitoxantrone 
resistance) and ABCP for (placental ABC transporter). BCRP was identified by Doyle 
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and colleagues in MCF7AdrVp, a breast cancer cell line selected for doxorubicin 
resistance that did not express Pgp or MRP1 (123). At the same time Allikmets and 
colleagues demonstrated BCRP expression in the placenta (124). Shortly thereafter, 
Maliepaard and colleagues demonstrated BCRP overexpression in an ovarian cancer cell 
line selected for topotecan resistance (125). BCRP is comprised of 663 amino acids and a 
single NBD at the amino terminus. BCRP domains are organized NH2-NBD-TMD-
COOH, giving the appearance of a half-transporter in contrast to Pgp and MRP (NH2-
TMD-NBD1-TMD-NBD2-COOH) (123). However, BCRP homodimerization is required 
for function (126).In addition to expression in placental syncytiotrophoblasts, BCRP is 
also expressed in the apical membrane of the small intestine epithelium, bile canaliculi, 
and the apical membrane of endothelial cells in brain vasculature (127).  
1.3.5.1 BCRP substrates 
BCRP transports a variety of xenobiotics and endogenous substrates (Table 1.8). 
Specifically, several studies have demonstrated that BCRP has a role in camptothecin 
analog resistance. The majority of data addressing the substrate specificity of each 
transporter has been generated using drug selected cell lines. Reduced accumulation and 
increased resistance to topotecan and SN-38 have been demonstrated in BCRP 
overexpressing cell lines selected for drug resistance (125,128). Because this selection 
process can produce numerous genetic and post-translational alterations, the most reliable 
substrate specificity data is generated in isogenic systems. Houghton and colleagues 
demonstrated that Saos2 cells transfected with ABCG2 and overexpressing BCRP are 12-
fold and 50-fold more resistant to topotecan and SN-38, respectively, than the vector 
control cell line (129).  All of  these  studies  taken  together  indicate  that  BCRP confers 
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Table 1.8 Partial list of BCRP substrates. 
 
Xenobiotic Substrates Endogenous Substrates 
Mitoxantrone E217βG 
Topotecan Estrone-3-sulfate 
Irinotecan, SN-38, SN-38 glucuronide Dehydroepiandrosterone 
Methotrexate, methotrexate 
polyglutamates 
 
 
Source:  Litman T, et al. The multidrug-resistant phenotype associated with 
overexpression of the new ABC half-transporter, MXR (ABCG2), J Cell Sci, 113 ( Pt 
11): 2011-2021, 2000.
 
resistance to the camptothecin analogs SN-38 and topotecan. 
1.3.5.2 BCRP in neuroblastoma 
The role of BCRP expression in neuroblastoma has not been studied extensively. 
In one study of the mRNA expression of ABC transporters in neuroblastoma, BCRP 
mRNA was detected in neuroblastoma tumor specimens from patients, but the level of 
mRNA expression was not related to treatment outcome (110). The only other study of 
BCRP expression in neuroblastoma used immunohistochemistry to demonstrate BCRP 
protein expression in the xenograft NB1691 (130). Therefore, the extent to which BCRP 
is expressed in neuroblastoma tumors in children and its role in response to camptothecin 
analogs is unknown. 
In summary, BCRP plays a role in camptothecin analog tumor resistance. 
Therefore, the contribution of BCRP to camptothecin analog resistance in neuroblastoma 
will be explored in this project. 
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1.3.6 Modifying ABC transporter function 
To determine the role of ABC transporters in drug resistance, the function and/ or 
expression of the transporter must be modulated. A small molecule chemical modulator 
can be used to inhibit transport or compete with substrates. Table 1.9 contains a partial 
list of small molecule chemical modulators of ABC transporters. However, no small 
molecule chemical inhibitor exists that inhibits a single ABC transporter. These chemical 
modulators of ABC transporters are therefore more useful in modulating the activity of a 
variety of transporters rather than in studying the contribution of a single transporter to 
resistance. 
Other useful approaches to investigate the function of specific transporters in 
neuroblastoma cells or normal tissues include gene knockout, RNA interference (RNAi), 
and overexpression. Null models in which the gene for a specific ABC transporter has 
been knocked out can be used both in vitro and in vivo. For example, differences in drug 
sensitivity between knockout and wild type MEFs can be determined in vitro to 
determine the contribution of basal ABC transporter expression in normal tissues (101). 
Knockout mice can be compared to wild-type mice in pharmacokinetic studies. However, 
this approach is laborious and expensive. Moreover, it does not directly test the function 
of the human transporter in a human system such as a cell line derived from a human 
tumor sample. Also, due to the variation in sensitivity of different tumor types to 
cytotoxic drugs, the contribution of ABC transporters to drug resistance in a particular 
tumor type should be studied in the tumor or cell line of interest. 
Exogenous overexpression of ABC transporters is another useful tool for studying 
ABC  transporter  function.  This   approach   has   been   used   consistently   to   identify 
 41
Table 1.9 Chemical modulators of ABC transporters. 
 
Drug Transporters Inhibited References 
Verapamil Pgp, MRP1, MRP4 (18,131,132) 
Quinidine Pgp, MRP1, MRP2 (18) 
Valspodar Pgp, MRP1 (18) 
MK571 MRP1, MRP2, MRP4, 
MRP7 
(133,134,112,135) 
Gefitinib Pgp, BCRP (130,136) 
GF120918 Pgp, BCRP (137,138,139,140) 
Indomethacin MRP1, MRP4 (141,118,112) 
 
Sources:  Litman T, et al. From MDR to MXR: new understanding of multidrug 
resistance systems, their properties and clinical significance, Cell and Molecular Life 
Sciences, 58: 931-959, 2001. 
 
Abe T, et al. Chemosensitisation of spontaneous multidrug resistance by a 1,4-
dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP 
or MDR1, Br J Cancer, 72: 418-423, 1995. 
 
Bai J, et al. Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-
glutathione, Int J Biochem Cell Biol, 36: 247-257, 2004. 
 
Leier I, et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 
and structurally related conjugates, J Biol Chem, 269: 27807-27810, 1994. 
 
Leier I, et al. ATP-dependent para-aminohippurate transport by apical multidrug 
resistance protein MRP2, Kidney Int, 57: 1636-1642, 2000. 
 
Jedlitschky G, et al. The nucleotide transporter MRP4 (ABCC4) is highly expressed in 
human platelets and present in dense granules, indicating a role in mediator storage, 
Blood, 104: 3603-3610, 2004. 
 
Chen ZS, et al. Characterization of the transport properties of human multidrug resistance 
protein 7 (MRP7, ABCC10), Mol Pharmacol, 63: 351-358, 2003. 
 
Stewart CF, et al. Gefitinib enhances the antitumor activity and oral bioavailability of 
irinotecan in mice, Cancer Res, 64: 7491-7499, 2004. 
 
Leggas M, et al. Gefitinib modulates the function of multiple ATP-binding cassette 
transporters in vivo, Cancer Res, 66: 4802-4807, 2006. 
 
Hyafil F, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an 
acridonecarboxamide derivative, Cancer Res, 53: 4595-4602, 1993. 
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Table 1.9 (continued) 
 
Allen JD, et al. Potent and specific inhibition of the breast cancer resistance protein 
multidrug transporter in vitro and in mouse intestine by a novel analogue of 
fumitremorgin C, Mol Cancer Ther, 1: 417-425, 2002. 
 
Maliepaard M, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated 
resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor 
GF120918, Clin Cancer Res, 7: 935-941, 2001. 
 
Allen JD, et al. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in 
cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin, Cancer Res, 
59: 4237-4241, 1999. 
 
Decleves X, et al. Molecular and functional MDR1-Pgp and MRPs expression in human 
glioblastoma multiforme cell lines, Int J Cancer, 98: 173-180, 2002. 
 
Reid G, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin 
efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs, Proc Natl 
Acad Sci U S A, 100: 9244-9249, 2003. 
 
Jedlitschky G, et al. The nucleotide transporter MRP4 (ABCC4) is highly expressed in 
human platelets and present in dense granules, indicating a role in mediator storage, 
Blood, 104: 3603-3610, 2004. 
 
 43
endogenous and xenobiotic substrates and to demonstrate multi-drug resistance. Cell 
lines overexpressing ABC transporters have the advantage over those with basal 
expression levels in that differences in substrate accumulation or resistance are more 
pronounced and easily detected. However, due to protein abundance this approach does 
not give much information about the role of normal, basal protein expression.  
RNA interference (RNAi) can be used to silence the expression of a specific gene. 
Just as for targeting the disruption of a particular gene locus to knock out a gene, RNAi 
can be used to study the contribution of basal gene expression to the phenotype of 
interest.  
RNAi was first described as double-stranded RNA (dsRNA) mediated sequence-
specific post transcriptional gene silencing in the nematode Caenorhabditis elegans 
(142). The highly conserved RNAi phenomenon of gene silencing has been observed in 
protozoa, invertebrates, vertebrates, plants, fungi, and algae. RNAi is hypothesized to 
serve as an antiviral defense mechanism (143,144). 
Experimentally, RNAi can be used to reduce or eliminate the expression of a 
protein by targeting its mRNA for degradation. Dicer, an RNase III-like enzyme cleaves 
long dsRNA molecules into 21- to 23-nucleotide small interfering RNAs (siRNAs) (145). 
Subsequently the siRNAs are incorporated into the RNAi-induced silencing complex 
(RISC). ATP activates the RISC complex to expose the antisense siRNA strand and bind 
the targeted complementary mRNA (146). Finally, the mRNA is degraded by 
exonucleases (147,148). Exogenously delivered RNAi used to inhibit ABC transporter 
function has an advantage over chemical inhibition due to specific targeting of a single 
gene.  
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Despite the ability to achieve targeted silencing of a single gene based upon 
nucleotide sequence complementarity, RNAi can induce nonspecific off-target effects 
that include the interferon response and concentration-dependent induction of off-target 
genes(149). The interferon response elicited by introduction of long dsDNA can be 
circumvented by introduction of siRNAs, which are short dsDNA molecules 21-22 bp in 
length that specifically target degradation of mammalian genes. Using the minimum 
effective siRNA concentration eliminates the induction of off-target or “siRNA-
response” genes (150).  
To achieve gene silencing with RNAi, the construct must be appropriately 
delivered to the target cell and can be transient or stable. RNAi can be delivered as small 
interfering RNA (siRNA) or short hairpin RNA (shRNA) oligonucleotides to achieve 
transient knockdown of a gene. Plasmids or retroviral vectors containing a shRNA 
cassette under the control of the RNA polymerase promoter (i.e., H1 or U6) can be used 
to achieve stable expression of RNAi. Brummelkamp and colleagues  achieved stable 
RNAi by including a puromycin resistance cassette in a plasmid containing the H1 
promoter and a 19-nt gene specific insert followed by a spacer to form a hairpin and then 
the reverse complement of the 19-nt sequence (151). Therefore, stable retroviral mediated 
RNAi will be used to silence ABC transporter expression in neuroblastoma cell lines to 
determine the contribution of basal expression to in vitro and in vivo camptothecin analog 
sensitivity. 
1.4 Summary 
High-risk neuroblastoma remains a significant clinical challenge despite 
aggressive and intense therapy. The camptothecin analogs topotecan and irinotecan are 
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useful components of neuroblastoma therapy. Despite a favorable anti-tumor response 
rate to pharmacokinetically guided topotecan in children with high-risk neuroblastoma, 
some patients failed to achieve a clinically meaningful response. Therefore, we postulate 
that molecular mechanisms of drug resistance were also present in primary 
neuroblastoma cells. Specifically we propose that Pgp, MRP1, MRP2, MRP4, and BCRP 
may be expressed in neuroblastoma and may confer resistance to topotecan and 
irinotecan/ SN-38. The primary hypothesis of this dissertation was that the expression of 
ABC transporters contributes to clinical resistance of neuroblastoma to the cytotoxicity of 
topotecan and irinotecan/ SN-38.  
1.5 Specific aims 
The primary objective of this work was to understand the role of ABC 
transporters in neuroblastoma resistance to the camptothecin analogs. Potentially relevant 
ABC transporters include Pgp, MRP1, MRP2, MRP4, and BCRP. To accomplish this 
objective we will use genetically modified neuroblastoma cell lines, xenograft models, 
and biopsy specimens from children with high-risk neuroblastoma.  
1.5.1 To determine the contribution of ABC transporters to topotecan and irinotecan 
sensitivity in neuroblastoma cell lines 
A panel of neuroblastoma cell lines representing a range of topotecan and 
irinotecan sensitivities will be evaluated to determine if differential expression of ABC 
transporters identifies specific transporters that may confer clinical resistance to the 
camptothecin analogs. RNAi will be used to silence MRP4 and Pgp in a resistant 
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neuroblastoma cell line. In addition, MRP4 will be overexpressed in a sensitive 
neuroblastoma cell line. 
1.5.2 To determine the role of MRP4 in neuroblastoma xenograft response to 
topotecan 
A murine xenograft model in which MRP4 has been silenced via RNAi will be 
established. Mice bearing neuroblastoma xenografts with silenced MRP4 will be treated 
with topotecan to assess the contribution of basal MRP4 expression to topotecan 
resistance in neuroblastoma in vivo. 
1.5.3 To determine the role of ABC transporter expression in response to topotecan 
in children with high-risk neuroblastoma 
Immunohistochemistry will be used to characterize the ABC transporter 
expression in neuroblastoma biopsy specimens from children with high-risk disease. The 
association between ABC transporter expression and response to pharmacokinetically 
guided topotecan will be evaluated. 
In summary, a subset of children with high-risk neuroblastoma did not respond to 
camptothecin analog based therapy. ABC transporters (e.g., MRP4 and Pgp) may 
contribute to this clinical resistance. These in vitro, in vivo, and clinical studies of 
neuroblastoma will help to define the role of MRP4 and Pgp in camptothecin analog 
resistance in neuroblastoma. 
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Chapter 2. MRP4 and P-glycoprotein confer resistance to 
topotecan in neuroblastoma 
2.1 Introduction 
Neuroblastoma is the most common extracranial solid tumor in children. The 
prognosis for children diagnosed with high-risk neuroblastoma is poor, with 5-year 
survival less than 30% (152). Topotecan and irinotecan anti-tumor activity in 
neuroblastoma has been demonstrated in preclinical studies and phase I clinical trials, 
including studies in children with high-risk disease (64,66,70,71,17,76,153). 
Furthermore, there is a steep topotecan systemic exposure/ anti-tumor response 
relationship. However, substantial interindividual variation in topotecan 
pharmacokinetics exists in children. Topotecan systemic clearance, the determinant of 
systemic exposure as measured by AUC, varies at least ten-fold in children (49). 
Therefore, dosing topotecan based solely on body surface area may lead to some anti-
tumor responses but also a range of toxic and subtherapeutic exposures. 
Minimizing interindividual variability in topotecan systemic exposure with a 
pharmacokinetically guided dosing approach has been successful in terms of achieving 
the putatively effective systemic exposure in children with high-risk neuroblastoma (15). 
In a phase II trial this pharmacokinetically guided dosing approach also resulted in very 
good anti-tumor activity. Out of 28 children with high-risk neuroblastoma evaluable for a 
response to pharmacokinetically guided topotecan, 1 complete response and 17 partial 
responses were observed. However, the ten children with tumors that failed to respond 
may represent a subset of the disease resistant to topotecan (49,154,155).  
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Although clinical resistance to topotecan is multi-factorial, ABC transporters have 
been implicated in multi-drug resistance in neuroblastoma. Pgp and MRP1 have been 
associated with diminished response of neuroblastoma to chemotherapy (52,156). Many 
of the drugs used to treat neuroblastoma are MRP1 and/ or Pgp substrates, including 
doxorubicin, vincristine, and etoposide. However, mechanistic studies validating a link 
between protein expression of ABC transporters and resistance to chemotherapeutic 
agents are lacking. Moreover, in neuroblastoma the expression of other members of the 
ABC transporter superfamily such as MRP2, MRP4, and BCRP has not been well 
characterized. 
We have previously demonstrated that topotecan is an MRP4 substrate (114). 
Topotecan, irinotecan, and SN-38 are BCRP substrates. Irinotecan and SN-38 are also 
MRP2 substrates (125,157,158). Several investigators have demonstrated that Pgp 
confers resistance to topotecan. In this study we used RNAi to reduce MRP4 and Pgp 
expression in neuroblastoma cell lines to evaluate the effect of ABC transporters on 
topotecan and irinotecan resistance. 
RNAi can be mediated through siRNA or shRNA. Reductions in protein 
expression mediated by siRNA are transient. In cell culture, this gene silencing persists 
for 3-5 days (159). Variation in transfection efficiency also limits the application of 
transient transfection of siRNA. Knock down via transient transfection of siRNA 
targeting ABC transporters is suitable to test certain phenotypes such as drug 
accumulation. However, this transient system is not suitable to test longer time-dependent 
phenotypes such as drug sensitivity using the MTT assay. 
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In contrast with transient siRNA-mediated downregulation of gene expression, 
retroviral vector mediated shRNA can persist for long periods of time, due to integration 
in the host genome. In addition, retroviral vectors can carry selection markers such as 
puromycin resistance genes or green fluorescent protein (GFP). Continuous selection 
pressure can be applied by culturing in the presence of puromycin. Alternatively, drug 
interactions or non-specific effects of selection antibiotics can be avoided using GFP as a 
selection marker. GFP expressing clones can be sorted by FACS, and GFP expression 
over time can be monitored via flow cytometry or fluorescence microscopy. But in all 
cases, reduced protein expression of the shRNA targeted gene must be confirmed. 
Thus, the objectives of the present study were to determine whether MRP4 and 
Pgp confer resistance to topotecan and SN-38 in neuroblastoma. Therefore, we used 
shRNA to knock down MRP4 and Pgp expression in the cell line NB1691. Furthermore, 
we overexpressed MRP4 in the cell line NB1643. These in vitro models were used to 
evaluate intracellular drug accumulation and sensitivity to camptothecin analogs. 
2.2 Materials and methods 
2.2.1 Chemicals and cell lines 
Topotecan, 3H-topotecan, and 14C-topotecan were generously provided by 
GlaxoSmithKline (King of Prussia, PA). SN-38, the active component of the pro-drug 
irinotecan (CPT-11) was provided by Pfizer (New York, NY). 
NB1691, NB1643, SKNAS, SKNSH, NBEB (also known as SJNB1), and NBSD 
(also known as SJNB4) cell lines were kindly provided by Dr. Peter Houghton (St. Jude 
Children’s Research Hospital, Memphis, TN). Saos2 pcDNA and Saos2 MRP4 cell lines 
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were kindly provided by Dr. John Schuetz (St. Jude Children’s Research Hospital). The 
amphotropic retroviral packaging cell line Phoenix was obtained from ATCC (Manassas, 
VA). Cells were maintained in RPMI 1640 (Mediatech, Herndon, VA), 10% FBS 
(HyClone, Logan, UT), and 1% L-glutamine (Mediatech) at 37°C, 5% CO2. 
2.2.2 Transient MDR1 siRNA 
Three siRNA constructs targeting MDR1 (Ambion, Austin, TX) were transfected 
(30 nM) into NB1691 using siPORT Amine (Ambion). The sequence targeting MDR1 
exon 4 was selected for further use in stable shRNA studies, and the primers 5’-GATCC-
CCGGGAAAAGAAACCAACTGTCTCAAGAGGACAGTTGGTTTCTTTTCCCTTT-
TTGGAAA-3’ and 5’-AGCTTTTCCAAAAAGGGAAAAGAAACCAACTGTCCTCT-
TGAGACAGTTGGTTTCTTTTCCCGGG-3’ containing BglII and HindIII half-sites 
were cloned into pSuper. 
2.2.3 Stable RNAi by cloning MRP4 or MDR1 shRNA into MSCVGFP 
The pSUPER42 (118) vector containing a MRP4 shRNA cassette was generously 
provided by Dr. Piet Borst (Netherlands Cancer Institute, Amsterdam, Netherlands). The 
MSCVGFP42 construct was made by cloning a SmaI and SalI fragment from pSUPER42 
containing the H1 promoter and MRP4 shRNA sequence into SalI and HindIII sites of 
MSCVGFP (160). The MSCV MDR1 shRNA GFP construct was made by cloning a 
SmaI and SalI fragment from pSuperMDR1shRNA into the SalI and HindIII sites of 
MSCVGFP. FuGENE6 (Roche Applied Science) was used to transfect MSCVGFP42, 
MSCV MDR1 shRNA GFP, or MSCVGFP into Phoenix producer cells. Retrovirus was 
harvested from Phoenix cells sorted for GFP expression, and NB1691 cells were 
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transduced with vector alone, the MRP4 knockdown construct MSCVGFP42, or the Pgp 
knockdown construct MSCV MDR1 shRNA GFP. Clones with stable MRP4 or Pgp 
knockdown were generated by sorting single NB1691 cells expressing GFP into 96-well 
plates, expanding, and screening by real-time RT-PCR and Western blot for MRP4 or 
Pgp expression. 
2.2.4 Cloning MRP4 into NB1643 
The MRP4 expression vector MSCV MRP4 IRES GFP containing an internal 
ribosomal entry site permitting co-expression of MRP4 and GFP (kindly provided by Dr. 
John Schuetz) was transfected into Phoenix cells (161). NB1643 cells were transduced 
with retrovirus harvested from cells sorted for GFP expression. NB1643 cells 
overexpressing MRP4 were selected by FACS, expanded, and screened by Western blot 
for MRP4 expression. 
2.2.5 Real-time RT-PCR 
RNA was extracted from cells with Tri-Reagent (Molecular Research Center, 
Cincinnati, OH), and cDNA was synthesized using a mixture of oligo-dT and random 
hexamer primers with the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA). 
Real-time PCR analysis was conducted using gene specific primers (Table 2.1) and 
QuantiTect SYBR Green PCR Kit (Qiagen) on the ABI Prism 7900HT (Applied 
Biosystems, Foster City, CA). Thermal cycling conditions were as follows: 15 min at 
95°C followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 30 s, and finally a 
denaturation stage. The mRNA expression level was determined by the comparative Ct 
method.  Fold-change  in  mRNA  expression  level  was   calculated   by   evaluating  the  
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Table 2.1 Primer sequences for real-time RT-PCR. 
 
Gene Primer Sense Primer Antisense Reference 
MDR1 CTGTATTGTTTGCCACCACGA 
 
AGGGTGTCAAATTTATGAGGCAGT 
 
(162) 
MRP4 CAGTACCTCAAAGCTGCAAGTC CCCAGTATGAAAGCCACCAA (163) 
BCRP CAGGAGGCCTTGGGATACTT 
 
TGCCACAGCAGTGGAATCT 
 
(164) 
GAPDH ACCACAGTCCATGCCATCAC 
 
TCCACCACCCTGTTGCTGTA 
 
(163) 
β-actin GAGCACAGAGCCTCGCCTTT TGACCCATGCCCACCATCAC  
 
Sources:  Wunderlich K, et al. Vasospastic persons exhibit differential expression of 
ABC-transport proteins, Mol Vis, 9: 756-761, 2003. 
 
Assem M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the 
constitutive androstane receptor and Mrp4 knockout mice, J Biol Chem, 279: 22250-
22257, 2004. 
 
Zamber CP, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and 
their relationship to BCRP expression in human intestine, Pharmacogenetics, 13: 19-28, 
2003. 
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expression 2-ΔΔCt where Ct is the cycle threshold, ΔCt is the difference in mean cycle 
threshold between the gene of interest and the normalizing gene (e.g., Ct MRP4-Ct GAPDH), 
and ΔΔCt is the difference between the ΔCt’s of the reference and test samples (e.g., ΔCt 
NB1691 - ΔCt NB1691 4.27). 
2.2.6 Western blot 
Membrane enriched fractions were isolated from cells by sonicating in 
homogenizing buffer (100 mM Tris-HCl, 100 mM KCl, 1 mM EDTA, and protease 
inhibitors, Roche Applied Science, Indianapolis, IN) and centrifugation at 18,000 x g for 
15 min. The pellet was resuspended in microsome storage buffer (100 mM KH2PO4, 1 
mM EDTA, 20% glycerol, and protease inhibitors), and DNA was sheared by passing 
through a 27 gauge needle. In some cases, membrane proteins were isolated using the 
Mem-PER Eukaryotic Membrane Protein Extraction Kit (Pierce, Rockford, IL).  
Detergents used in the Mem-PER protein isolation were removed using the PAGEprep 
Advance Clean-Up Kit (Pierce). 
Protein was quantitated by Bradford Assay (Bio-Rad, Hercules, CA). Proteins (10 
μg per lane) were separated by SDS-PAGE (4-12% Bis-Tris gel, MOPS running buffer, 
Invitrogen, Carlsbad, CA) and transferred to PVDF membranes. Blots were probed with 
the polyclonal rabbit-anti-human MRP4, kindly provided by Dr. John Schuetz, or the 
monoclonal antibodies M4I-10 (rat anti-human and mouse MRP4, Axxora, San Diego, 
CA), BXP-21 (mouse anti-human BCRP, Kamiya Biomedical, Seattle, WA), AC-15 
(mouse anti-human β-actin, Sigma, St. Louis, MO), and JSB-1 (mouse anti-human Pgp, 
Signet Labs, Dedham, MA). Proteins were visualized with ECL Plus (Amersham 
Biosciences, Piscataway, NJ). 
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Membrane samples that appeared to express MRP4 with a higher molecular 
weight than the positive control were treated with the enzyme PNGaseF (New England 
Biolabs, Ipswich, MA) to deglycosylate proteins. For this reaction, 10μg of membrane 
protein were denatured in the reaction buffer for 10 min at 37°C. Then 500 units 
PNGaseF was added for a 1 hr incubation at 37°C.  
2.2.7 Intracellular topotecan, PMEA, rhodamine 123, and mitoxantrone 
accumulation 
Neuroblastoma cells were plated in 6-well plates (300,000 cells/well) in media 
without phenol red and allowed to attach overnight. 3H-topotecan or 14C-topotecan was 
added (final concentration of 10 μM, 3H-topotecan specific activity 100 dpm/pmol and 
14C-topotecan specific activity 30 dpm/pmol) for 6 hr at 37°C.  MRP4 function was 
assessed by PMEA intracellular accumulation. Bis(POM)3H-PMEA (Moravek 
Biochemicals, Brea, CA) was added (10 μM) and incubated at 37°C for 20 hr. The media 
was removed, and cells were washed once in ice-cold PBS. Cells were detached by 
addition of 0.5 N NaOH and acidified with 1 N HCl. Intracellular 3H-topotecan, 14C-
topotecan, or 3H-PMEA was measured by scintillation counting with normalization to 
total protein content. 
Pgp function was assessed by intracellular rhodamine accumulation in 106 
neuroblastoma cells incubated for 30 min with 0.1 mg/mL rhodamine 123 (165). 
Intracellular fluorescence was determined by FACS.  Pgp function in cells expressing 
GFP, which fluoresces in the same channel as rhodamine 123, was assessed by 
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intracellular 3H-mitoxantrone (Moravek Biochemicals) accumulation, as described for 
radiolabeled topotecan and PMEA. 
2.2.8 MTT assay 
Cells were plated in RPMI 1640 without phenol red, 10% FBS, and 1% L-
glutamine in 96-well plates (10,000 cells/well) and allowed to attach overnight. Cells 
were exposed to various concentrations of topotecan (1 nM to 200 μM) or SN-38 (1 nM 
to 100 μM) for 6 hr, and the media was replaced. Viability was assessed 4 days later by 
the addition of MTT (Sigma, St. Louis, MO) for 3 hr. Formazan crystals produced only 
by viable cells were solubilized with 0.04 N HCl in isopropanol. Absorbance was 
measured at 570 nm with wavelength correction at 650 nm on the μQuant Microplate 
Spectrophotometer (Bio-Tek Instruments, Winooski, VT).  
2.2.9 Statistical considerations 
The drug concentration that inhibited 50% of cell growth (IC50) was calculated 
according to the Michaelis-Menten equation. Student’s t-test with Bonferroni correction 
was used to determine differences in IC50 between control and transduced neuroblastoma 
cell lines. Dunnett’s multiple comparison tests was used to determine differences in 
intracellular drug accumulation between control and transduced neuroblastoma cell lines. 
All tests were two-tailed. 
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2.3 Results  
2.3.1 Functional MRP4 and Pgp expression in neuroblastoma cell lines resistant to 
camptothecin analogs 
Since expression of ABC transporters confers resistance to topotecan and 
irinotecan/SN38, we evaluated the expression of Pgp, MRP1, MRP2, MRP4, and BCRP 
in six neuroblastoma cell lines. We determined that MRP1 was expressed in all 
neuroblastoma cell lines representing a spectrum of sensitivity to topotecan. In contrast, 
neither MRP2 nor BCRP was expressed in vitro in these six neuroblastoma cell lines. 
Next, we determined that both MRP4 and Pgp were differentially expressed in the six 
neuroblastoma cell lines (Figure 2.1). Both MRP4 and Pgp were expressed in NB1691. 
However, neither MRP4 nor Pgp were expressed in NB1643. SKNAS also expressed 
MRP4 but not Pgp. SKNSH expressed Pgp but not MRP4. 
We also measured intracellular accumulation of the MRP4 substrate PMEA 
(Figure 2.2A). NB1691 and SKNAS, the two cells lines that expressed MRP4, exhibited 
the lowest intracellular PMEA accumulation, consistent with the hypothesis that MRP4 
was functionally active and effluxing PMEA. In contrast, NB1643 accumulated the 
highest level of intracellular PMEA. 
Likewise, to demonstrate functional expression of Pgp, we measured intracellular 
accumulation of the Pgp substrate rhodamine 123 (Figure 2.2B). The two Pgp expressing 
cell lines NB1691 and SKNSH accumulated the least rhodamine intracellularly, 
suggesting the presence of a functionally active efflux transporter. The highest rhodamine 
accumulation was observed in NB1643, consistent with the lack of an efflux transporter. 
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 Figure 2.1 MRP4 and Pgp expression in topotecan resistant neuroblastoma cell 
lines.  
The blot was probed with polyclone rabbit-anti-human MRP4 antibody. The negative and 
positive controls are from Saos2 pcDNA and Saos2 MRP4 cell lysates, respectively. 
MRP4 is expressed in NB1691 and SKNAS. The lower molecular weight band present in 
all samples is a non-specific band. Pgp is expressed in NB1691 and SKNSH. NB1643 
expresses neither MRP4 nor Pgp. 
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Figure 2.2 Accumulation of the MRP4 and Pgp substrates PMEA and 
rhodamine 123 in neuroblastoma cell lines.  
PMEA accumulation is the lowest in the MRP4 expressing cell lines in NB1691 and 
SKNAS. The highest PMEA accumulation was observed in NB1643, which does not 
express MRP4 (A). Pgp expression in NB1691 and SKNSH leads to reduced intracellular 
accumulation of rhodamine 123. The highest rhodamine accumulation occurs in NB1643, 
which lacks Pgp expression (B).  
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 To evaluate whether the expression of ABC transporters was related to topotecan 
sensitivity in this panel of six neuroblastoma cell lines, we determined the IC50 to a six hr 
topotecan exposure by MTT assay. The topotecan IC50 was 8 μM for NB1691 and 0.4 
μM for NB1643 (Figure 2.3A). This 20-fold increased topotecan resistance in NB1691 is 
accompanied by reduced topotecan intracellular accumulation (Figure 2.3B) in NB1691 
compared to NB1643, consistent with drug efflux as a resistance mechanism in NB1691. 
The next highest topotecan IC50 was observed in SKNSH, which expressed Pgp but not 
MPR4.  
2.3.2 Functional MRP4 knockdown with stably expressed shRNA  
Due to MRP4 and Pgp expression in the two neuroblastoma cell lines most 
resistant to topotecan, and a lack of MRP4 or Pgp expression in the neuroblastoma cell 
line most sensitive to topotecan, we took two approaches to determine the relative 
contribution of MPR4 or Pgp to resistance. First, we used RNAi to reduce the expression 
of either MRP4 or Pgp in NB1691 and determine if there was an increase in sensitivity to 
the camptothecin analogs. The second approach to determine the contribution of MRP4 
to camptothecin analog sensitivity was to overexpress MRP4 in NB1643 and determine if 
there was an increase in resistance to camptothecin analogs. 
Using retroviral mediated expression of MRP4 shRNA, both MRP4 protein and 
mRNA expression were reduced in NB1691 GFP4.2 clones 7 and 9 compared to both the 
parental and vector only cell lines (Figure 2.4, Figure 2.5). Functional knockdown of 
MRP4 was confirmed by increased PMEA accumulation in NB1691 4.2 7 and 4.2 9 
(Figure 2.6). Functional knockdown of MRP4 resulted in increased sensitivity to 
topotecan 4-fold and 2-fold in clones 4.2 7 and 4.2 9, respectively (Figure .2 7). 
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Figure 2.3 H-3 Topotecan sensitivity and accumulation in neuroblastoma cell 
lines. 
The topotecan IC50 determined by MTT assay after a 6 hr exposure to the drug is 8 μM 
for NB1691 and 0.4 μM for NB1643 (A). Less 3H-topotecan accumulates intracellularly 
in the resistant NB1691 compared NB1643 (B). 
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Figure 2.4 Immunoblot analysis of MRP4 expression in NB1691 cells transduced 
with MRP4 shRNA. 
MRP4 expression was reduced in the NB1691 clones transduced with the retrovirus 
carrying the MRP4 shRNA and GFP cassettes. β-actin expression is depicted as the 
loading control.  
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Figure 2.5 Real-time RT-PCR analysis in NB1691 MRP4 shRNA clones. 
MRP4 mRNA expression is reduced in clones 4.2 7 and 4.2 9 compared to the parental 
cell line and vector control. Values are presented as mean ± standard deviation.* P≤ 0.01 
(t-test with Bonferroni correction). 
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Figure 2.6 PMEA intracellular accumulation in NB1691 MRP4 shRNA clones. 
Intracellular PMEA accumulation was determined after a 20 hr incubation with Bis-
POM-PMEA. Reduced MRP4 expression in clones 4.2 7 and 4.2 9 results in an increase 
in PMEA intracellular accumulation, indicating functional knockdown of MRP4. Values 
are presented as mean ± standard deviation. * P≤ 0.001 (Dunnett’s test). 
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Figure 2.7 Topotecan sensitivity in NB1691 MRP4 shRNA clones. 
Viability curve derived from MTT assay of NB1691 and clones with reduced MRP4 
expression demonstrates increased topotecan sensitivity in clones 4.2 7 and 4.2 9. The 6 
hr topotecan IC50 is lower in NB1691 clones with reduced MRP4 expression compared to 
the parental cell line (inset). Viability is presented as mean ± standard deviation with the 
best fit line. IC50 values are presented as mean IC50 estimate (95% confidence interval) 
(B). * P≤ 0.01 (t-test with Bonferroni correction). 
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Furthermore, knocking down MRP4 expression resulted in 2-fold increased SN-38 
sensitivity in clones 4.2 7 and 4.2 9 (Figure 2.8). We also evaluated the sensitivity to the 
prodrug irinotecan in the clones with reduced MRP4 expression, but there was no 
difference between the parental control and clones 4.2 7 and 4.2 9 (data not shown). 
2.3.3 Functional MRP4 overexpression in NB1643 
After demonstrating that topotecan and SN-38 sensitivity increased upon 
reduction of MRP4 expression, we evaluated the effect of MRP4 overexpression in 
NB1643. MRP4 protein levels were 1.4- fold higher in NB1643 MRP4 IRES GFP 
compared to the parental cell line, as determined by densitometry (Figure 2.9). These 
samples were subjected to enzymatic deglycosylation because we observed slight 
variation in MRP4 electrophoretic migration between NB1643 and the Saos2 control 
cells. We reasoned that the observed differences in MRP4 molecular weight among cell 
lines may be due to differential glycosylation. Protein band intensity increased upon 
deglycosylation with PNGaseF, indicating that the M4I-10 antibody may have more 
specificity for deglycosylated MRP4 than the native glycoprotein. 
MRP4 expression in NB1643 resulted in reduced intracellular accumulation of 
PMEA, indicating the presence of functional MRP4 (Figure 2.10A). PMEA accumulation 
in NB1643 MSCV MRP4 IRES GFP was 20% lower than in NB1643 (P≤0.01), 
proportional to the MRP4 expression level. In the Saos2 MRP4 control cell line, PMEA 
accumulation was 2-fold lower than the vector control (Figure 2.10B). Functional 
expression of MRP4 in NB1643 resulted in an increase in camptothecin analog 
resistance. The 6 hr topotecan IC50 was 7-fold higher in NB1643 MRP4 compared to
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Figure 2.8 SN38 sensitivity in NB1691 MRP4 shRNA clones. 
Viability curve derived from MTT assay of NB1691 and clones with reduced MRP4 
expression demonstrates increased SN-38 sensitivity in clones 4.2 7 and 4.2 9. The 6 hr 
SN-38 IC50 is lower in NB1691 clones with reduced MRP4 expression compared to the 
parental cell line (inset). Viability is presented as mean ± standard deviation with the best 
fit line. IC50 values are presented as mean IC50 estimate (95% confidence interval). * P≤ 
0.01 (t-test with Bonferroni correction). 
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 Figure 2.9 Immunoblot analysis of MRP4 expression in NB1643 cells transduced 
with MSCV MRP4 IRES GFP. 
The blot was probed with the monoclonal M4I-10 antibody. MRP4 is overexpressed in 
NB1643 cells transduced with MSCV MRP4 IRES GFP. PMEA accumulation is reduced 
in cells overexpressing MRP4. Sensitivity to topotecan and SN-38 decreases in NB1643 
cells overexpressing MRP4. 
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Figure 2.10 Intracellular PMEA accumulation in NB1643 cells overexpressing 
MRP4. 
MRP4 overexpression in NB1643 results in 20% decrease in intracellular PMEA 
accumulation, indicating the presence of a functional efflux transporter (A). PMEA 
accumulation in the control Saos2 cell line was reduced 2-fold in the MRP4 
overexpressing cell line Saos2 MRP4 (B). Values are presented as mean ± standard 
deviation.* P≤ 0.005 (Dunnett’s multiple comparison test). 
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NB1643 (Figure 2.11). The 6 hr SN-38 IC50 was 1.5-fold higher in NB1643 MRP4 
compared to NB1643 (Figure 2.12). 
2.3.4 Functional Pgp knockdown with stably expressed shRNA 
Based upon the preliminary screen of six neuroblastoma cell lines in which Pgp 
was expressed in the most resistant cell line to topotecan, we also evaluated the effect of 
reducing Pgp expression in NB1691. The shRNA construct targeting MDR1 mRNA for 
degradation resulted in a significant decrease in MDR1 expression in clones 1, 2, and 3 
(Figure 2.13). 
Intracellular mitoxantrone accumulation was used to assess functional Pgp 
knockdown in the NB1691 MDR1 shRNA clones. Rhodamine 123 could not be used as a 
probe for Pgp function because rhodamine 123 and GFP fluoresce in the same channel. In 
the Pgp overexpressing cell line LLCPK1 MDR1, mitoxantrone accumulation was 
significantly reduced compared to LLCPK1, consistent with mitoxantrone as a Pgp 
substrate. Mitoxantrone accumulation was significantly higher (2-fold) in NB1691 
MDR1 shRNA clones 1, 2, and 3 than in the parental NB1691, consistent with reduced 
Pgp function (Figure 2.14). Furthermore, topotecan accumulated intracellularly at higher 
levels in MDR1 shRNA clones 1 and 3 (Figure 2.15A). Further confirming topotecan as a 
Pgp substrate, topotecan accumulation was reduced in the Pgp overexpressing LLCPK1 
MDR1 in comparison to the vector control (Figure 2.15B). Finally, the reduction in Pgp 
function and increased topotecan accumulation resulted in increased sensitivity to 
topotecan. The topotecan IC50 was 2- to 5-fold lower than NB1691 in MDR1 shRNA 
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Figure 2.11 Topotecan sensitivity in NB1643 cells overexpressing MRP4. 
Viability curve derived from MTT assay of NB1643, NB1643 IRES, and NB1643 MRP4 
demonstrates reduced topotecan sensitivity in the cell line overexpressing MRP4. The 6 
hr topotecan IC50 is significantly higher in NB1643 MRP4 compared to the parental cell 
line (inset). Viability is presented as mean ± standard deviation with the best fit line. IC50 
values are presented as mean IC50 estimate (95% confidence interval). * P≤ 0.01 (t-test 
with Bonferroni correction). 
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Figure 2.12 SN-38 sensitivity in NB1643 cells overexpressing MRP4. 
Viability curve derived from MTT assay of NB1643, NB1643 IRES, and NB1643 MRP4 
demonstrates reduced SN-38 sensitivity in the cell line overexpressing MRP4 (mean ± 
standard deviation, best fit line). The 6 hr SN-38 IC50 is significantly higher in NB1643 
MRP4 compared to the parental cell line. Values are presented as mean IC50 estimate 
(95% confidence interval) (B). * P≤ 0.01 (t-test with Bonferroni correction). 
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Figure 2.13 Real-time RT-PCR analysis of in NB1691 MDR1 shRNA clones. 
MDR1 mRNA expression is reduced in clones 1, 2, and 3 compared to the parental cell 
and vector control. Values are presented as mean ± standard deviation.* P≤ 0.01 (t-test 
with Bonferroni correction). 
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Figure 2.14 Intracellular mitoxantrone accumulation in NB1691 MDR1 shRNA 
clones. 
Reduced Pgp expression in MDR1 shRNA clones 1, 2, and 3 results in an increase in 
mitoxantrone intracellular accumulation, indicating functional knockdown of Pgp (A). 
Mitoxantrone accumulation is reduced in the Pgp overexpressing cell line LLCPK1 
MDR1 (B). Values are presented as mean ± standard deviation. * P≤ 0.001 (Dunnett’s 
multiple comparison test). 
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Figure 2.15 Intracellular 14C-topotecan accumulation in NB1691 MDR1 shRNA 
clones. 
Reduced Pgp expression in MDR1 shRNA clones 1 and 3 results in an increase in 
topotecan intracellular accumulation (A). Topotecan accumulation is significantly 
reduced in the Pgp overexpressing cell line LLCPK1 MDR1 (B). Values are presented as 
mean ± standard deviation. * P≤ 0.001 (Dunnett’s multiple comparison test). 
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clones 2 and 3 (Figure 2.16). However, reduced Pgp expression and function did not 
result in increased sensitivity to SN-38 (Figure 2.17). To determine if this unexpected 
phenotype was related to an increase in expression of other ABC transporters such as 
MRP2, we used real-time RT-PCR to evaluate mRNA expression. However, MRP2 was 
expressed at low levels in all of the cell lines, and no statistically significant difference 
was noted in expression level among the cell lines (data not shown). 
2.4 Discussion 
In this study we have shown that ABC transporter expression confers 
camptothecin analog resistance in neuroblastoma cell lines. Furthermore, reducing ABC 
transporter expression via shRNA reduces camptothecin analog resistance. The ABC 
transporters MRP4 and Pgp, which confer resistance to topotecan and SN-38 
(89,114,120,122), were expressed and functional in neuroblastoma cell lines relatively 
resistant to topotecan. In contrast, MRP4 and Pgp were not expressed in NB1643, which 
is relatively sensitive to topotecan. The differences in sensitivity to topotecan between 
NB1643 and NB1691 are not likely due to p53 status because both of these cell lines are 
wild-type p53 (166,167,168). These in vitro results are consistent with previous in vivo 
xenograft studies in which NB1643 xenografts responded to a topotecan systemic 
exposure of 52 ng/mL*hr (61). In contrast, a topotecan systemic exposure of 290 
ng/mL*hr was required to achieve a complete response in NB1691 xenografts. The 
results of the current study may explain the mechanisms of camptothecin analog 
resistance in some neuroblastomas. 
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Figure 2.16 Topotecan sensitivity in NB1691 MDR1 shRNA clones 
Viability curve derived from MTT assay of NB1691 and MDR1 shRNA clones 2 and 3 
demonstrates increased topotecan sensitivity in clones 2 and 3. The 6 hr topotecan IC50 is 
statistically significantly lower in clones 2 and 3 expressing MDR1 shRNA compared to 
the parental cell line (inset). Values are presented as mean IC50 estimate (95% confidence 
interval) (B). * P≤ 0.01 (t-test with Bonferroni correction). 
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Figure 2.17 SN-38 sensitivity in NB1691 MDR1 shRNA clones. 
Viability curve derived from MTT assay of NB1691 and MDR1 shRNA clones 2 and 3 
demonstrates increased SN-38 resistance in clone 3. The 6 hr topotecan IC50 is 
statistically significantly higher in clone 3 expressing MDR1 shRNA compared to the 
parental cell line (inset). Values are presented as mean IC50 estimate (95% confidence 
interval) (B). * P≤ 0.01 (t-test with Bonferroni correction). 
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  The initial results of immunoblot analysis of ABC transporter expression in 
neuroblastoma cell lines representing a spectrum of topotecan sensitivities indicated that 
MRP4 and Pgp may be partly responsible for resistance to camptothecin analogs in 
neuroblastoma. Therefore, to determine the individual contribution of MPR4 and Pgp to 
camptothecin analog resistance, we used RNAi to reduce MRP4 or Pgp expression in 
NB1691 and evaluate the effect on drug resistance. Knocking down MRP4 expression 
resulted in reduced MRP4 function, i.e., increased intracellular accumulation of the 
MRP4 substrate PMEA and topotecan. Reduced MRP4 expression and function also 
resulted in increased sensitivity to both topotecan and SN-38. Moreover, exogenous 
MRP4 overexpression conferred topotecan and SN-38 resistance in a neuroblastoma cell 
line relatively sensitive to topotecan and SN-38. 
As observed for MRP4, shRNA to Pgp reduced Pgp expression and function. In 
NB1691 clones with reduced Pgp expression, intracellular accumulation of mitoxantrone, 
a probe for Pgp function was increased. Topotecan intracellular accumulation was also 
increased, resulting in increased sensitivity. However, reduced Pgp functional expression 
did not result in an increase in SN-38 sensitivity. We reasoned that this may be due to a 
compensatory increase in expression of an ABC transporter for which SN-38, but not 
topotecan, is a substrate, such as MRP2. However, MRP2 expression did not differ 
among the NB1691 MDR1 shRNA clones or controls. Therefore, we postulate that the 
observed increase in SN-38 resistance in NB1691 MDR1 shRNA clone 3 may be due to 
increased intracellular inactivation of the drug. 
Although neuroblastoma xenograft models and patients exhibit responses to the 
camptothecin analogs, there is a sensitivity continuum among both patients and 
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xenografts. For example, NB1691 and NB143 were isolated from patients with stage D 
neuroblastoma (70). NB1643 was established from a diagnostic tumor sample. In 
contrast, the patient from whom NB1691 was derived had received prior therapy 
including cytarabine, daunomycin, 6-thioguanine, etoposide, and 5-azacytidine. This 
multi-agent chemotherapy may have acted as a selective pressure for a neuroblastoma 
clonal population that expresses ABC transporters. However, it is also possible that the 
ABC transporters expressed in NB1691 were present at the onset of disease and before 
chemotherapeutic selection of resistant clones. Without a paired tumor specimen isolated 
prior to therapy, it is not possible to determine whether NB1691 represents intrinsic or 
acquired resistance. Regardless, we have demonstrated that NB1691 is a model of ABC 
transporter mediated resistance to camptothecin analogs. 
The findings that MRP4 and Pgp mediate resistance to the camptothecin analogs 
in neuroblastoma have several potential applications. A gene therapy approach using 
RNAi to knock down the expression of ABC transporters in the tumor may increase the 
sensitivity of neuroblastoma to topotecan or irinotecan. Reducing the expression of ABC 
transporters at the level of the tumor may also increase the sensitivity to other drugs 
traditionally used in neuroblastoma, such as doxorubicin, vincristine, etoposide, and 
cyclophosphamide. In addition to inhibiting ABC transporters by reducing protein 
expression, drugs designed to inhibit ABC transporters such as valspodar or biricodar 
may theoretically help to increase tumor levels of cytotoxic drugs. However, MDR 
modulators have not significantly improved outcome in clinical trials (169,170,171). 
In contrast to the MDR modulators biricodar or valspodar, other drugs that were 
not initially designed as modulators of MDR have been shown to modulate MDR as a 
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“side effect.” For example, the EGFR tyrosine kinase inhibitor gefitinib also inhibits 
BCRP and Pgp (130,136). Combining gefitinib (or other similar compounds such as 
erlotinib) with topotecan or irinotecan can take advantage of the cytostatic effect of 
gefitinib in addition to its ability to increase tumor levels of cytotoxic compounds. 
However, gefitinib inhibits ABC transporters expressed in normal tissues (e.g., kidney) 
important in the pharmacokinetics of topotecan and irinotecan. Therefore, the interaction 
between camptothecin analogs and EGFR tyrosine kinase inhibitors can be three-fold: 
increasing camptothecin analog systemic exposure, inhibiting camptothecin analog efflux 
from malignant cells, and pharmacologic interaction between EGFR inhibition and 
topoisomerase I interaction. 
Finally, the results of the current study may be useful in future trials of 
individualizing therapy for patients with neuroblastoma. Determining the ABC 
transporter expression profile on a diagnostic tumor sample can be used to select drugs 
that are not substrates for the transporters expressed in an individual patient’s tumor. 
However, the possibility remains that no drugs currently available will be predicted to be 
effective in some children, especially with high-risk disease. Therefore, further 
development of drugs that evade the ABC transporters and other resistance mechanisms 
in children with neuroblastoma is required to improve the survival rate. 
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Chapter 3. Effect of MRP4 shRNA on NB1691 xenograft 
response to topotecan  
3.1 Introduction 
Murine xenograft models are a useful preclinical tool for assessing response of 
human tumors to chemotherapeutic agents. Anti-tumor response can be measured in 
xenograft-bearing mice treated with various drugs or drug combinations. Furthermore, 
various dosages and schedules of drug administration can be compared in murine 
xenograft models. 
A panel of six neuroblastoma xenograft models demonstrated a range of 
responses to topotecan (155). A complete response to 3 intravenous topotecan courses 
administered daily for 5 days for two weeks ([(dx5)2]3) was achieved in 4 of the 6 
xenograft models at a dosage of 0.61 mg/kg. In contrast to the xenografts that responded 
to topotecan, the relatively resistant neuroblastoma xenograft model NB1691 required a 
topotecan dosage as high as 2 mg/kg to achieve a complete response. But a partial 
response to this [(dx5)2]3 topotecan schedule was observed in NB1691 at a dosage of 1 
mg/kg. 
Efflux of topotecan by ABC transport proteins has been implicated in resistance 
to topotecan. In a screen of ABC transport protein expression of neuroblastoma cell lines 
cultured in vitro, we demonstrated that the relatively resistant NB1691 expressed both 
MRP4 and Pgp (172), and topotecan is a substrate for both MRP4 and Pgp (114). 
However, the relatively sensitive NB1643 did not express MRP4 or P-glycoprotein. 
Therefore, we hypothesized that knocking down MRP4 or P-glycoprotein expression in 
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NB1691 would increase the sensitivity of NB1691 to camptothecin analogs and yield a 
response profile similar to NB1643 both in vitro and in vivo. As described in Chapter 2, 
the in vitro studies of topotecan sensitivity in NB1691 in which shRNA was used to 
reduce MRP4 expression demonstrated an increase in topotecan sensitivity. 
The objective of this study was to evaluate the contribution of MRP4 expression 
in neuroblastoma to tumor response to topotecan in vivo. Therefore, we established the 
NB1691 MRP4 shRNA clones as xenografts in SCID mice. We measured the xenograft 
response to topotecan [(dx5)2]3 at dosages previously shown to elicit partial and 
complete responses in the NB1691 xenograft model. 
3.2 Materials and methods 
3.2.1 Knockdown via stable shRNA 
MRP4 expression in NB1691 was knocked down in vitro using shRNA as 
described in Chapter 2. Single cell clones were selected by FACS, expanded, and 
characterized by Western blot and in vitro cytotoxicity assays. Cells (1x108) were 
harvested and transplanted into the flanks of CB17/Icr female scid -/- mice.  
3.2.2 Growth inhibition studies 
Mice bearing s.c. tumors received topotecan when tumors were ~0.20 to 1 cm in 
diameter (173). Tumor diameters were measured weekly using Vernier calipers. 
Assuming tumors to be spherical, tumor volumes were calculated according to the 
formula [(π/6) x d3] where d is the mean diameter. Tumor bearing mice were randomized 
into groups of ten prior to therapy. One group was treated with vehicle control, and a 
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second group was treated with topotecan. All mice were housed under barrier conditions. 
All experiments were conducted using protocols and conditions approved by the St. Jude 
Children’s Research Hospital Institutional Animal Care and Use Committee. 
3.2.3 Drugs and formulation 
Topotecan (GlaxoSmithKline, King of Prussia, PA) was formulated in 0.9% 
saline and administered i.v. (0.05 mL/10g body weight) at a dose of 1 or 2 mg/kg as a 
short injection (<1 minute) into the lateral tail vein. Mice received topotecan [(dx5)2]3. 
3.2.4 Real-time RT-PCR 
RNA was extracted from xenograft tissue with Tri-Reagent (Molecular Research 
Center, Cincinnati, OH), and cDNA was synthesized using a mixture of oligo-dT and 
random hexamer primers with the QuantiTect Reverse Transcription Kit (Qiagen, 
Valencia, CA). Real-time PCR analysis was conducted using gene specific primers as 
described in Chapter 2. Thermal cycling conditions were as follows: 15 min at 95°C 
followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 30 s, and finally a 
denaturation stage. The mRNA expression level was determined by the comparative Ct 
method. Student’s t-test (two-tailed) with Bonferroni correction was used to determine 
differences in mRNA expression between NB1691 and MRP4 shRNA clones. 
3.2.5 Immunohistochemistry 
Neuroblastoma xenograft tissues were fixed in formalin and embedded in 
paraffin. Sections (4 μm) were placed on positively charged slides. Slides were heated 
(60°C) for 30 minutes and cleared of paraffin in CitriSolv (Fisher Scientific, Hampton, 
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NH) and alcohol gradient solution panel prior to high temperature antigen recovery in 
citrate buffer pH 6.0. Slides were blocked with 3% hydrogen peroxide in methanol and 
avidin/ biotin blocking reagent (Vector Labs, Burlingame CA) prior to incubation with 
the primary antibody. Irrelevant isotype fractions were used as negative controls. 
Biotinylated secondary antibodies were used (Vector Labs), and the tertiary reagent was 
streptavidin-horseradish peroxidase (Dako, Carpinteria, CA). Color development was 
achieved with diaminobenzidine (DAB, Dako), and the slides were counterstained with 
hematoxylin (Dako). 
3.3 Results 
As described in Chapter 2, the retroviral-vector mediated MRP4 shRNA reduced 
MRP4 mRNA and protein expression in NB1691 clones 4.2 7 and 9 in vitro. When these 
clones were transplanted into SCID mice as xenografts, all 4 cell lines (NB1691 parental, 
GFP1 vector control, and clones 4.2 7 and 9) grew and developed palpable tumors. 
However, on the second passage in vivo, clone 4.2 7 did not develop palpable tumors. 
To determine the effect of reducing MRP4 expression in NB1691 on xenograft 
response to topotecan, mice were treated at a topotecan dosage and schedule that had 
previously elicited a partial response in NB1691 (1 mg/kg [(dx5)2]3). We hypothesized 
that reduced MRP4 expression would be associated with a more pronounced antitumor 
response in comparison to the parental cell line. Unexpectedly, none of the tumors 
responded to topotecan 1 mg/kg (Figure 3.1). Therefore, we treated the xenografts on the 
same schedule at a higher topotecan dosage (2 mg/kg). Again, unexpectedly none of the 
xenografts responded to the higher topotecan dosage (Figure 3.2). NB1691GFP 4.2 7 was  
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Figure 3.1 NB1691 MRP4 shRNA xenograft response to i.v. topotecan 1 mg/kg 
[(dx5)2]3. 
Tumor volume was measured weekly until tumor volume quadrupled. Mice were treated 
with vehicle control (A-D) or topotecan daily for 5 days for 2 weeks every 21 days for up 
to 3 courses (E-H). NB1691 (A, E); NB1691 GFP1 (B, F); NB1691 GFP 4.2 7 (C, G); 
NB1691 GFP 4.2 9 (D, H). Each curve represents the growth of an individual tumor. 
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 Figure 3.2 NB1691 MRP4 shRNA xenograft response to i.v. topotecan 2 mg/kg 
[(dx5)2]3. 
Tumor volume was measured weekly until tumor volume quadrupled. Mice were treated 
with vehicle control (A-C) or topotecan daily for 5 days for 2 weeks every 21 days for up 
to 3 courses (D-F). NB1691 (A, D); NB1691 GFP1 (B, E); NB1691 GFP 4.2 9 (C, F). 
Each curve represents the growth of an individual tumor. 
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not included at the 2 mg/kg dosage because the xenografts did not grow after the second 
passage in vivo. 
To determine if ineffective MRP4 knockdown was related to failure to respond in 
the NB1691 xenograft clones, we evaluated the MRP4 mRNA and protein expression in 
the xenografts. In clone 4.2 7, real-time RT-PCR analysis demonstrated that MRP4 
mRNA expression was approximately half the mRNA level in the parental xenograft 
(Figure 3.3). Whereas, in vitro, the MRP4 mRNA expression level in clone 4.2 7 was 
only 10% of the parental cell line (Figure 2.5). However, in clone 4.2 9 MRP4 mRNA 
expression was not significantly reduced compared to NB1691 (Figure 3.3), indicating 
that the MRP4 shRNA did not persist in this clone. Microscopic evaluation of xenograft 
sections revealed green fluorescence, indicating that the GFP cassette had not been 
silenced. Immunohistochemical staining of MRP4 in the NB1691 xenografts 
demonstrated heterogeneous MRP4 expression in all four xenografts (Figure 3.4). 
Therefore, effective MRP4 knockdown via shRNA did not persist in this in vivo 
xenograft model. 
Upregulation of other ABC transporters for which topotecan is a substrate may be 
responsible for the lack of response in the MRP4 shRNA xenografts. Therefore we also 
evaluated MDR1 and BCRP mRNA expression. MDR1 mRNA expression was only 
significantly elevated in the GFP1 vector only xenograft (Figure 3.5). However, the 
observed level of MDR1 expression in all four xenograft models may be sufficient to 
confer in vivo resistance to topotecan. Real-time RT-PCR analysis demonstrated that 
BCRP mRNA was expressed at low levels (Ct of approximately 30) in all four xenograft 
models, and no significant difference was observed in expression level among them (data 
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Figure 3.3 MRP4 mRNA expression in NB1691 MRP4 shRNA xenografts. 
MRP4 mRNA expression is significantly reduced in NB1691 4.2 7 but not 4.2 9.*P<0.01 
(t-test with Bonferroni correction). 
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Figure 3.4 MRP4 is expressed in NB1691 MRP4 shRNA xenografts. 
Immunohistochemical analysis of NB1691 MRP4 shRNA xenografts showing 
heterogeneous membrane staining of MRP4 (brown stain). NB1691 (A); NB1691 GFP1 
(B); NB1691 4.2 7 (C); NB1691 4.2 9(D). MRP4 shRNA did not effectively reduce the 
MRP4 expression in NB1691 xenografts. 
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Figure 3.5 MDR1 mRNA expression in NB1691 MRP4 shRNA xenografts. 
MDR1 mRNA expression is significantly increased in NB1691 GFP1. *P<0.01 (t-test 
with Bonferroni correction).  
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not shown). BCRP was not expressed in the four xenograft models as determined by 
immunohistochemical analysis. Therefore, in vivo expression of BCRP does not account 
for the failure of these xenografts to respond to topotecan. 
3.4 Discussion 
In order to determine the contribution of MRP4 expression in vivo to response to 
topotecan, we established the NB1691 clones transduced with MRP4 shRNA as 
xenografts. SCID mice were treated with a protracted topotecan schedule that had 
previously elicited a partial response in CBA/CaJ mice bearing NB1691 xenografts 
(61).Unexpectedly, none of the 4 xenograft models responded to 1 or 2 mg/kg topotecan 
[(dx5)2]3. To determine if MRP4 silencing via shRNA persisted in xenografts, we 
analyzed MRP4 expression by real-time RT-PCR and immunohistochemistry. MRP4 
mRNA expression was higher in vivo than in vitro. In addition, results of 
immunohistochemical analysis demonstrated that MRP4 was heterogeneously expressed 
in all four xenografts. Therefore, effective MRP4 shRNA did not persist in vivo. 
However, expression of MRP4 in these four xenograft models and failure to respond to 
topotecan are consistent with the hypothesis that MRP4 expression confers resistance to 
topotecan. 
The lack of response to topotecan of the parental NB1691 xenograft may be 
attributable to variations in tumor growth or response in different strains of mice. The 
partial response of NB1691 to 1 mg/kg topotecan was observed in CBA/CaJ mice (61). 
The current study was conducted in SCID mice. Thompson and colleagues demonstrated 
that NB1691 xenografts in SCID mice were less sensitive to topotecan than in the 
CBA/CaJ host (174). 
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Topotecan pharmacokinetics are similar in SCID and CBA/CaJ mice (Dr. Clinton 
Stewart, unpublished data), so the difference between strains is not attributable to 
variations in systemic exposure. SCID mice bearing NB1691 xenografts did not respond 
to oral topotecan 2 mg/kg (Chris Morton, personal communication May 30, 2006). In 
SCID mice the topotecan systemic exposure after an oral dose of 2 mg/kg is 55 ng/mL*hr 
(136), approximately equivalent to that achieved by 0.36 mg/kg i.v. topotecan. In 
CBA/CaJ mice bearing NB1691 xenografts, a partial response was achieved in mice 
treated with 0.36mg/kg i.v. topotecan, indicating that variations in mouse strain may 
impact the response of NB1691 xenografts to topotecan. 
The NB1691 cell line used to establish xenografts had been maintained in tissue 
culture. Cell lines maintained in tissue culture are subject to alterations (175) that may 
influence sensitivity to cytotoxic drugs including topotecan. For example, promoter 
methylation and silencing of apoptosis-related genes can occur during passage in tissue 
culture (176). Genetic instability including chromosomal gains, losses, or translocation 
and gene amplification or deletion can also accumulate during tissue culture passage 
(176). Enhanced recombinatorial repair of topotecan-induced DNA strand breaks has 
been implicated in camptothecin analog resistance and may occur during passage over 
time in culture (177). Inhibition of cell death signaled by topotecan-induced DNA lesions 
may also result in topotecan resistance. Alternatively, enhanced activity of the DNA 
repair enzyme MGMT can result in topotecan resistance (178). Any of these alterations 
may account for the failure to respond to topotecan in vivo. 
Despite the decreased sensitivity of NB1691 xenografts in SCID mice, we 
predicted that xenografts derived from the MRP4 shRNA clones would be more sensitive 
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to topotecan than the parental cell line. However, we did not observe differences in vivo 
response based on MRP4 expression.  
Failure of the MRP4 shRNA may be attributed to retroviral vector silencing. Gene 
expression has been silenced in retroviral vectors containing the MLV LTR. This 
silencing is mediated by the binding of ELP, an embryonal LTR-binding protein that 
suppresses transcription of the MLV LTR. However, expression of the MRP4 shRNA 
cassette in the MSCV retroviral vector that we used was directed by the PCMV LTR in 
which the ELP binding site has been deleted, decreasing the potential for retroviral vector 
silencing (160,179). Furthermore, GFP expression in all of the transduced xenografts was 
visualized with fluorescence microscopy, suggesting that the retroviral vector was not 
silenced in vivo. 
The disparity in the effect of MRP4 expression on topotecan sensitivity observed 
in vitro and in vivo may also be due in part to differences in the in vitro and in vivo 
environments. For example, Mattern et al demonstrated that resistance conferred by ABC 
transporters in vitro was not be recapitulated in vivo for the camptothecin analogs (73). 
Pgp expression in vitro conferred 15-35 fold resistance to topotecan. In contrast, Pgp 
expression in vivo did not significantly alter topotecan sensitivity. 
The hypoxic tumor microenvironment may contribute to the disparity between in 
vitro and in vivo sensitivity to topotecan observed in our studies. MRP4 expression may 
have been induced in the hypoxic tumor microenvironment, overwhelming any RNAi-
mediated knockdown in MRP4 expression. Recent in vitro studies have demonstrated 
increased MRP4 mRNA expression in NB1691 after 24 hours of hypoxia (Dr. Stacy 
Throm, personal communication March 14, 2007). BCRP expression is also induced 
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under hypoxia via the HIF-1 pathway in placental choriocarcinoma, osteosarcoma, and 
acute myelogenous leukemia cell lines (180). The hypoxic tumor microenvironment 
stands in contrast to the oxygen replete in vitro environment that permits persistent 
MRP4 knockdown and differential topotecan sensitivity based on MRP4 expression. 
The results of these studies highlight the differences between in vitro and in vivo 
environments. While we observed shRNA mediated MRP4 reduction in vitro that 
correlated with increased sensitivity to the camptothecin analogs, the same patterns were 
not recapitulated in the xenograft models.  
Although the goal of these experiments was to determine the effect of MRP4 
expression in vivo on the response of neuroblastoma to topotecan, the results do not 
provide an answer to this research question. However, because all of the NB1691 clones 
studied herein expressed MRP4 and failed to respond to topotecan, the results of these 
studies are consistent with the hypothesis that MRP4 expression confers resistance to 
topotecan and may be a factor in failure of some neuroblastomas to respond. Future 
studies in which MRP4 can be effectively silenced in vivo will be required to address this 
issue definitively. 
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Chapter 4. ABC transporter expression in neuroblastoma 
biopsy specimens from children treated with 
pharmacokinetically guided topotecan 
4.1 Introduction 
The camptothecin analog topotecan is active against neuroblastoma in preclinical 
xenograft models. Based on the preclinical activity of topotecan in models of childhood 
solid tumors, topotecan has been evaluated in phase I and II clinical trials in children. In a 
phase II trial of topotecan in 30 children with high-risk neuroblastoma, a complete 
response was observed in 1 child, and partial responses were observed in 17 children for 
a response rate of 60% (15). Despite this favorable response to topotecan, a higher 
response rate was predicted based upon the anti-tumor activity of topotecan in 
neuroblastoma xenograft models. The 40% of children with high-risk neuroblastoma who 
did not respond to topotecan represent a subset of the population resistant to topotecan. 
We have also demonstrated in neuroblastoma cell lines in vitro that the ABC 
transporters MRP4 and Pgp confer topotecan resistance. Thus, the objective of the current 
study was to evaluate the potential relation between ABC transport protein expression 
and clinical response to topotecan. Therefore, we evaluated the expression of ABC 
transporters for which topotecan is a substrate (i.e., MRP4, Pgp, and BCRP) in tumor 
specimens from children enrolled on the phase II trial of topotecan in high-risk 
neuroblastoma. We used immunohistochemistry to determine the plasma membrane 
expression of ABC transport proteins in neuroblastoma samples. 
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4.2 Materials and methods 
4.2.1 Patients 
All patients evaluated in this retrospective study were enrolled on a phase II trial 
of pharmacokinetically guided topotecan at St. Jude Children’s Research Hospital (15). 
Patients enrolled on the phase II trial had previously untreated high-risk neuroblastoma 
(i.e., INSS stage 3 or 4 disease in children older than 1 year or MYCN amplified stage 3 
or 4 disease in children younger than 1 year). The St. Jude Institutional Review Board 
approved this retrospective study. 
4.2.2 Tumor specimens 
We attempted to evaluate ABC transporter expression in bone marrow aspirates 
obtained prior to therapy. However, the acid decalcification of these specimens prevented 
effective antigen retrieval and immunohistochemical detection of the proteins of interest. 
Therefore, we used formalin-fixed paraffin-embedded tumor specimens obtained during 
resection of the primary tumor after two cycles of topotecan and standard induction 
therapy including cyclophosphamide, doxorubicin, etoposide, cisplatin, ifosfamide, and 
carboplatin. 
4.2.3 Definitions of response to pharmacokinetically guided topotecan 
Response to pharmacokinetically guided topotecan was evaluated after two cycles 
and defined by extent of tumor regression. A complete response (CR) was more than 
90% regression of the primary tumor and complete resolution of metastatic disease. A 
partial response (PR) was more than 50% regression of all disease. An objective response 
 97
(OR) was 25-50% tumor regression. Stable disease (SD) was less than 25% tumor 
regression without tumor progression. Patients with a CR or PR were classified as 
responders, and those with OR or SD were classified as non-responders. Standard 
radiographic methods (e.g., CT scans, MRI scans) were used to evaluate response. 
4.2.4 Immunohistochemistry 
Sections (4 μm) of formalin-fixed paraffin-embedded neuroblastoma were placed 
on positively charged slides. Slides were heated (60°C) for 30 minutes and cleared of 
paraffin in CitriSolv (Fisher Scientific, Hampton, NH) and alcohol gradient solution 
panel prior to high temperature antigen recovery in citrate buffer pH 6.0. Slides were 
blocked with 3% hydrogen peroxide in methanol and avidin/ biotin blocking reagent 
(Vector Labs, Burlingame CA) prior to incubation with the primary antibody. MRP4 was 
probed with the rat anti-human monoclonal antibody M4I-10 (Axxora). BCRP was 
probed with the rat anti-human and mouse monoclonal antibody BXP-53 (Axxora). Pgp 
was probed with the mouse anti-human monoclonal antibody JSB-1 (Signet Labs). 
Irrelevant isotype fractions were used as negative controls. Biotinylated secondary 
antibodies were used (Vector Labs), and the tertiary reagent was streptavidin-horseradish 
peroxidase (Dako, Carpinteria, CA). Color development was achieved with DAB (Dako), 
and the slides were counterstained with hematoxylin (Dako). Human kidney sections 
were used as positive controls for MRP4, Pgp, and BCRP staining. 
Stained slides were visualized under a light microscope at 40x magnification. 
Only tumors with membrane staining of tumor cells were considered positive for 
expression of the individual transporters. Staining of endothelial cells within the tumor 
was not scored as positive. 
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4.2.5 Statistical considerations 
The Fisher exact test was used to determine if the children for whom tumor 
samples were available were representative of the study population in terms of response 
to topotecan. The Fisher exact test was also used to determine if ABC transporter 
expression was a significant indicator of response to topotecan. All tests were two-tailed. 
4.3 Results 
Neuroblastoma sections were available from 14 out of 28 evaluable patients. The 
positive and negative controls in human kidney are depicted in Figure 4.1. MRP4, Pgp, 
and BCRP are expressed in the brush border of the proximal convoluted tubule. No 
staining was noted in the isotype negative controls.  
Out of the 14 available neuroblastoma sections, MRP4 was expressed in 2, Pgp 
was expressed in 4, and BCRP was expressed in 9 (Table 4.1). Neuroblastomas from four 
of eight responders expressed at least one of the ABC transporters evaluated. Tumors 
from four of the six non-responders expressed at least one of the ABC transporters 
evaluated. The neuroblastoma section from patient nine was representative of all 
specimens in which MRP4 was not expressed (Figure 4.2A). MRP4 was expressed in the 
membrane of neuroblastoma cells from patient number seven (Figure 4.2B). Pgp was not 
expressed in the neuroblastoma specimen from patient 13 (Figure 4.2C). Pgp was 
localized to the plasma membrane of neuroblastoma cells from patient number ten 
(Figure 4.2D), but was heterogeneous and localized to only a few regions of the tumor 
specimen. This pattern of sporadic Pgp staining was representative of all Pgp positive 
specimens. BCRP was not expressed in the neuroblastoma cells from patient three 
(Figure 4.2E). The  tumor  from  patient two expressed BCRP (Figure 4.2F). 
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Figure 4.1 ABC transporter expression in human kidney controls. 
Left column: irrelevant IgG negative control. Right column: positive control. Rat IgG 
(A); M4I-10 (B); Mouse IgG (C); JSB-1 (D); Rat IgG (E); BXP-53 (F). Brown staining in 
panels B, D, and F indicate localization of MRP4, Pgp, and BCRP to brush border of the 
proximal tubules. All images are shown at 40x magnification. 
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Table 4.1 ABC transporter expression in neuroblastoma specimens and 
response to pharmacokinetically guided topotecan. 
 
Patient Number Response MRP4 
expression 
Pgp 
expression 
BCRP 
expression 
1 PR - - - 
2 PR - - + 
3 PR - - - 
4 PR - - + 
5 PR - + + 
6 PR - + + 
7 PR + - + 
8 PR + - - 
9 OR - - + 
10 OR - + + 
11 SD - - - 
12 SD - - + 
13 SD - - - 
14 SD - + + 
 
Abbreviations: MRP4- multi-drug resistance associated protein 4; Pgp- P-glycoprotein; 
BCRP- breast cancer resistance protein; PR-partial response; OR- objective response; 
SD- stable disease 
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 Figure 4.2 ABC transporter expression in neuroblastoma tissue obtained during 
primary tumor resection. 
Patient 9: MRP4 negative (A); Patient 7: MRP4 positive (B); Patient 13: Pgp negative 
(C); Patient 10: Pgp positive (D); Patient 3: BCRP negative (E); Patient 2: BCRP positive 
(F). All images are shown at 40x magnification. 
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Despite expression of MRP4, Pgp, or BCRP in neuroblastoma, these ABC 
transporters were not statistically related to response to pharmacokinetically guided 
topotecan (P> 0.05, Fisher Exact test). There was an essentially even distribution of ABC 
transporter protein expression among responders and non-responders to topotecan. 
However, this was a small sample size and may not be sufficiently powered to detect a 
difference in ABC transporter expression between responders and non-responders. 
4.4 Discussion 
We used immunohistochemistry to detect the expression of MRP4, Pgp, and 
BCRP in primary neuroblastoma sections and determined the relation to topotecan 
response. When compared to methods such as RT-PCR to detect mRNA expression 
(10,11,12,110) this immunohistochemical approach prevented contamination of ABC 
transporter expression in normal cells (e.g., vascular endothelium) that may obscure 
results. This immunohistochemical approach also permitted detection of ABC 
transporters localized to the plasma membrane of neoplastic cells  
Based on the possibility of chemotherapy related induction or selection of ABC 
transporters, we initially attempted to determine the ABC transporter expression profile 
in bone marrow aspirates obtained prior to therapy. However, acid decalcification of the 
bone marrow aspirates prevented antigen retrieval and detection of ABC transporter 
expression. Due to the availability of formalin-fixed, paraffin-embedded primary tumor 
tissue we decided to evaluate the ABC transporter expression in these samples. However, 
these tumors were resected after two topotecan cycles and standard multi-agent induction 
therapy. In these available samples, expression of MRP4, Pgp, or BCRP was not related 
to failure to respond to topotecan. 
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Previous studies have demonstrated that high levels of Pgp and MRP4 mRNA 
expression are predictive of poor outcome in neuroblastoma. Several factors may explain 
why a relation between MRP4/Pgp/BCRP expression and the clinical response to 
pharmacokinetically guided topotecan was not detected in the current study. The ABC 
transporter expression profile in the primary tumor may have changed as a result of 
induction therapy. Whereas cyclophosphamide, doxorubicin, and etoposide may be 
subject to ABC transporter mediated resistance, cisplatin, ifosfamide, and carboplatin 
may have eliminated the MRP4/Pgp/BCRP expressing clones responsible for failure to 
respond to topotecan. Although this phenomenon is the rationale for multi-agent 
chemotherapy, exposure of the neuroblastoma specimens to these drugs may have 
confounded our results. 
Norris and colleagues demonstrated MRP4 mRNA expression in 100% of 52 
neuroblastomas from untreated patients (110). In this population of 52 patients, high 
MRP4 mRNA expression was a significant indicator of poor survival. The previous 
studies demonstrating a relation between ABC transporter expression and outcome 
evaluated mRNA, not protein expression (11,12,10). Although the real-time RT-PCR 
method permits simple and rapid quantitation of mRNA expression in tumor homogenate, 
this method does not necessarily isolate tumor tissue from normal tissue such as blood 
vessels. This is particularly problematic for the ABC transporters, which are expressed in 
vascular endothelial cells. Furthermore, the tissue must be preserved in order to isolate 
high quality RNA, and a technique such as laser capture microdissection should be used 
to isolate neuroblastoma cells from endothelia (181). Immunohistochemistry permits 
detection of ABC transporter subcellular localization. Cytosolic localization of a 
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transporter would not likely result in resistance because the transporter is not oriented to 
efflux substrates from the cell. 
Whether response to topotecan predicts long-term outcome such as overall 
survival or event-free-survival remains to be determined. Evaluating whether the ABC 
transporter protein expression profile in the primary or metastatic tumor at any point 
(before, during, or after therapy) predicts outcome may help to improve the response of 
neuroblastoma to the camptothecin analogs. To accomplish this in a clinical study of 
children with neuroblastoma, the question about correlation between ABC transporter 
mRNA and protein expression must first be addressed. ABC transporter expression in the 
same tumor sample should be evaluated using both real-time RT-PCR and 
immunohistochemistry. Next, ABC transporter expression should be evaluated before 
and after therapy to determine the influence of chemotherapy on ABC transporter 
expression. Finally, a clinical study should be sufficiently powered to determine the 
relationship between ABC transporter expression and clinical outcome in children with 
neuroblastoma.
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Chapter 5. Summary and future directions 
Neuroblastoma is the most common extracranial solid tumor in children. Patients 
who present with localized disease have excellent predicted survival. However, most 
children diagnosed with neuroblastoma are at high-risk for a poor outcome because they 
present with metastatic disease and/ or other unfavorable biological features including 
MYCN amplification. Therapy for children who are diagnosed with high-risk disease can 
include multi-agent chemotherapy, myeloablation with bone marrow transplant/ stem cell 
rescue, surgery, and radiation. Despite this intense therapy, five-year survival in children 
with high-risk neuroblastoma is much less favorable than for those with low- or 
intermediate-risk disease (30 to 40% compared to 80 to 95%). 
One of the approaches recently evaluated for improving the outcome in children 
with high-risk neuroblastoma is pharmacokinetically guided topotecan dosing (49,15). 
This approach was based on significant anti-tumor activity of topotecan systemic 
exposures of 100 ng/mL*hr in neuroblastoma xenograft models. Because topotecan 
clearance in children varies at least 10-fold and in animal models topotecan anti-tumor 
activity depends on systemic exposure, topotecan dosage was individualized to achieve a 
targeted systemic exposure of 80 to 120 ng/mL*hr in children with newly diagnosed 
high-risk neuroblastoma. Pharmacokinetically guided topotecan dosing was feasible in 
this population, and the response to this single agent was considered excellent. However, 
a significant proportion of children (40%) did not respond to topotecan and represent a 
subset of the disease that is resistant to topotecan. 
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ABC transporter mediated efflux of topotecan from neoplastic cells has been 
implicated in topotecan resistance. The ABC transporters for which topotecan is a 
substrate include Pgp, MRP1, MRP4, and BCRP. ABC transporters also confer resistance 
to other cytotoxic drugs traditionally used in high-risk neuroblastoma therapy (i.e., 
doxorubicin, etoposide, and vincristine). Furthermore, MRP1, Pgp, and MRP4 are 
expressed in neuroblastoma, and high levels of mRNA expression of these transporters is 
predictive of poor overall survival and event-free survival (10,11,12,110). However, the 
relation between expression of ABC transport proteins in neuroblastoma cells and anti-
tumor response to ABC transporter substrates has not been evaluated. 
The major objective of these studies was to evaluate the relation between 
expression of ABC transport proteins in neuroblastoma and response to the camptothecin 
analogs topotecan and SN-38. The first specific aim was to determine the contribution of 
ABC transporters to topotecan and irinotecan/SN-38 sensitivity in neuroblastoma cell 
lines. After identifying ABC transporters that confer resistance to camptothecin analogs 
in vitro, we evaluated the contribution of ABC transporter expression in neuroblastoma 
xenografts to topotecan response in vivo. Finally, we assessed the relation between 
expression of ABC transporters in neuroblastoma biopsy specimens and the anti-tumor 
response to pharmacokinetically guided topotecan. 
First, by western blot analysis we screened a panel of neuroblastoma cell lines 
with a range of sensitivity to topotecan for expression of ABC transporters. NB1691, the 
most topotecan resistant cell line evaluated, expressed both MRP4 and Pgp. In contrast, 
NB1643, the most topotecan sensitive cell line evaluated, expressed neither MRP4 nor 
Pgp. Based upon these results, we determined the effect of reducing MRP4 and Pgp 
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expression via shRNA in NB1691 on topotecan and SN-38 sensitivity. As expected, 
topotecan sensitivity increased in NB1691 clones with reduced MRP4 and Pgp protein 
expression. We also demonstrated that topotecan sensitivity was reduced upon 
overexpression of MRP4 in NB1643. 
To determine if the increased in vitro topotecan sensitivity in NB1691 MRP4 
shRNA clones translated into increased sensitivity in vivo, we established these NB1691 
clones as xenografts in SCID mice. Mice bearing neuroblastoma xenografts were treated 
with topotecan at dosages that had been shown to elicit at least 50% tumor volume 
regression in NB1691 xenografts (155). Unexpectedly, no tumor regression was observed 
in any of the xenografts evaluated. Furthermore, no difference was noted in response to 
topotecan between the parental NB1691 and the MRP4 shRNA clones. Most likely this 
occurred because MRP4 knock down did not persist in vivo. 
Because the rationale for this study of ABC transporters in camptothecin analog 
resistance was based upon the failure to respond to topotecan in 40% of children with 
high-risk neuroblastoma in a phase II trial, we also retrospectively evaluated the ABC 
transporter expression profile in neuroblastoma specimens from that phase II trial. Based 
on the in vitro data demonstrating increased sensitivity to topotecan in neuroblastoma 
clones with reduced MRP4 and Pgp expression, we reasoned that MRP4 and/ or Pgp 
would be expressed in neuroblastoma tissue from children who did not respond to 
topotecan. However, results of immunohistochemical detection of ABC transport protein 
in the membrane of neuroblastoma cells demonstrated that expression of MRP4, Pgp, or 
BCRP was not related to response to topotecan. Because this analysis could not be 
conducted on tissue prior to therapy, the results may be confounded by the effects of 
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multi-agent chemotherapy. Including tumor samples obtained prior to chemotherapy and 
preserved to ensure optimal antigen recovery in future clinical studies of neuroblastoma 
may permit a broader assessment of the impact of ABC transporter expression on anti-
tumor activity of drugs. 
The findings from the in vitro and xenograft studies conflict with the results of 
evaluation of clinical samples from children with neuroblastoma. The in vitro studies 
demonstrated that MRP4 and Pgp confer resistance to topotecan. The xenograft studies 
pointed towards a potential association between MRP4 expression and failure to respond 
to topotecan. But the lack of association between ABC transporter expression in the 
clinical samples and response to topotecan may be confounded by the timing of sample 
acquisition after two topotecan courses and induction therapy. More than highlighting the 
limitations of experimental models of neuroblastoma, the implications of our results also 
highlight the importance of determining ABC transporter expression prior to potential 
clonal selection by multi-agent chemotherapy in children with neuroblastoma. However, 
further preclinical xenograft studies and clinical studies will have to be conducted to 
determine the contribution of ABC transporter protein expression to response to 
individual drugs and overall outcome in neuroblastoma. 
The ABC transporter superfamily is only one class of proteins that influences 
anti-tumor response to drugs used in neuroblastoma therapy. Novel determinants of 
response could also be identified using mRNA gene expression arrays or single 
nucleotide polymorphism (SNP) chip arrays on laser capture microdissected tumor tissue. 
If tumor samples can be obtained at discrete time points during therapy including at 
diagnosis, after induction, consolidation, and bone marrow transplant, therapy could 
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potentially be individualized and optimized based upon changes in gene expression 
signature. 
Further preclinical studies could also be conducted to assess the effect of ABC 
transporter expression on anti-tumor response in neuroblastoma. For example, a mouse 
model of neuroblastoma could be developed to address the contribution of ABC 
transporters to tumor pathology and response to drugs. To accomplish this, the MRP4 
deficient mouse (114), for example, could be crossed with the transgenic mouse model 
overexpressing MYCN in neuroectodermal cells(182). Other ABC transporter knock out 
models including Bcrp and Mdr1a/1b models could also be crossed with the MYCN 
transgenic mouse. If the progeny of these crosses were viable, neuroblastoma 
development could be compared to the parental MYCN transgenic mouse to assess the 
role of ABC transporters in tumor formation. If tumors form in the progeny, they could 
be treated with various drugs including topotecan and irinotecan to determine the effect 
of ABC transporters on tumor response. But there is a caveat that the absence of an ABC 
transporter in normal tissues such as the kidneys will alter the pharmacokinetics of the 
drug. So an appropriate dosage that yields equivalent systemic exposures in the MYCN 
transgenic mouse and the MRP4 knockout/ MYCN transgenic progeny must be 
determined empirically. 
As ABC transporter expression is upregulated by hypoxia in osteosarcoma, acute 
myelogenous leukemia, and choricarcinoma cell lines(180), the role of hypoxia in 
resistance to topotecan and irinotecan should be assessed. In future xenograft studies, 
administration of RNAi in vivo (183) may permit more precise control over reduction of 
ABC transporter expression in the hypoxic tumor microenvironment.  
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Pharmacokinetically guided topotecan in combination with other agents (e.g., 
etoposide (184), cyclophosphamide (3), vincristine (185), and gefitinib (130,136)) may 
be an effective approach to improve long-term survival in high-risk neuroblastoma and 
other pediatric cancers. In evaluating these combinations, it will be important to use 
appropriate drug sequences, schedules, dosages, and systemic exposures in order to 
minimize host toxicity and maximize anti-tumor response. Additional analysis of the role 
of ABC transport protein expression in clinical response to these combinations may 
further improve the utility of the camptothecin analogs in neuroblastoma. 
In conclusion, our studies show that MRP4 and Pgp confer resistance to topotecan 
and SN38 in neuroblastoma. We developed an RNAi approach to silencing the 
expression of these ABC transporters in neuroblastoma to determine the contribution to 
camptothecin analog resistance. Future studies in children with neuroblastoma will 
further delineate the clinical relevance of our findings. The application of these data in 
the care of children with neuroblastoma may ultimately improve clinical outcome. 
 
 111
List of References 
 112
 1.  Grovas A, Fremgen A, Rauck A, Ruymann FB, et al. The National Cancer Data 
Base report on patterns of childhood cancers in the United States, Cancer, 80: 
2321-2332, 1997. 
 2.  Castleberry RP. Neuroblastoma, Eur J Cancer, 33: 1430-1437, 1997. 
 3.  Kretschmar CS, Kletzel M, Murray K, Thorner P, et al. Response to paclitaxel, 
topotecan, and topotecan-cyclophosphamide in children with untreated 
disseminated neuroblastoma treated in an upfront phase II investigational 
window: a pediatric oncology group study, J Clin Oncol, 22: 4119-4126, 2004. 
 4.  Ireland CM, Pittman SM, Jones SL, and Harnett PR. Establishment of an in vitro 
model for cisplatin resistance in human neuroblastoma cell lines, Anticancer Res, 
14: 2397-2403, 1994. 
 5.  Timmer-Bosscha H, Mulder NH, and de Vries EG. Modulation of cis-
diamminedichloroplatinum(II) resistance: a review, Br J Cancer, 66: 227-238, 
1992. 
 6.  Yasuno T, Matsumura T, Shikata T, Inazawa J, et al. Establishment and 
characterization of a cisplatin-resistant human neuroblastoma cell line, Anticancer 
Res, 19: 4049-4057, 1999. 
 7.  Ho R, Eggert A, Hishiki T, Minturn JE, et al. Resistance to chemotherapy 
mediated by TrkB in neuroblastomas, Cancer Res, 62: 6462-6466, 2002. 
 8.  Hetman M, Kanning K, Cavanaugh JE, and Xia Z. Neuroprotection by brain-
derived neurotrophic factor is mediated by extracellular signal-regulated kinase 
and phosphatidylinositol 3-kinase, J Biol Chem, 274: 22569-22580, 1999. 
 9.  Lee WP. Purification and characterization of tubulin from parental and 
vincristine-resistant HOB1 lymphoma cells, Arch Biochem Biophys, 319: 498-
503, 1995. 
 10.  Norris MD, Bordow SB, Marshall GM, Haber PS, et al. Expression of the gene 
for multidrug-resistance-associated protein and outcome in patients with 
neuroblastoma, N Engl J Med, 334: 231-238, 1996. 
 11.  Haber M, Bordow SB, Haber PS, Marshall GM, et al. The prognostic value of 
MDR1 gene expression in primary untreated neuroblastoma, Eur J Cancer, 33: 
2031-2036, 1997. 
 12.  Haber M, Smith J, Bordow SB, Flemming C, et al. Association of high-level 
MRP1 expression with poor clinical outcome in a large prospective study of 
primary neuroblastoma, J Clin Oncol, 24: 1546-1553, 2006. 
 113
 13.  Seeger RC, Brodeur GM, Sather H, Dalton A, et al. Association of multiple 
copies of the N-myc oncogene with rapid progression of neuroblastomas, N Engl 
J Med, 313: 1111-1116, 1985. 
 14.  Manohar CF, Bray JA, Salwen HR, Madafiglio J, et al. MYCN-mediated 
regulation of the MRP1 promoter in human neuroblastoma, Oncogene, 23: 753-
762, 2004. 
 15.  Santana VM, Furman WL, Billups CA, Hoffer F, et al. Improved response in 
high-risk neuroblastoma with protracted topotecan administration using a 
pharmacokinetically guided dosing approach, J Clin Oncol, 23: 4039-4047, 2005. 
 16.  Kushner BH, Kramer K, LaQuaglia MP, Modak S, et al. Reduction from seven to 
five cycles of intensive induction chemotherapy in children with high-risk 
neuroblastoma, J Clin Oncol, 22: 4888-4892, 2004. 
 17.  Furman WL, Stewart CF, Poquette CA, Pratt CB, et al. Direct translation of a 
protracted irinotecan schedule from a xenograft model to a phase I trial in 
children, J Clin Oncol, 17: 1815-1824, 1999. 
 18.  Litman T, Druley TE, Stein WD, and Bates SE. From MDR to MXR: new 
understanding of multidrug resistance systems, their properties and clinical 
significance, Cell and Molecular Life Sciences, 58: 931-959, 2001. 
 19.  Vasilatou-Kosmidis H. Cancer in neonates and infants, Med Pediatr Oncol, 41: 7-
9, 2003. 
 20.  Gurney JG, Severson RK, Davis S, and Robison LL. Incidence of cancer in 
children in the United States. Sex-, race-, and 1-yr. age-specific rates by histologic 
groups, Cancer, 75: 2186-2195, 1995. 
 21.  Brodeur GM and Castleberry RP. Neuroblastoma. In: Pizzo PA and Poplack DG 
(eds.), Principles and Practice of Pediatric Oncology, pp. 761-789. Lippincott-
Raven Publishers: Philadelphia, PA, 1997. 
 22.  Escobar MA, Grosfeld JL, Powell RL, West KW, et al. Long-term outcomes in 
patients with stage IV neuroblastoma, J Pediatr Surg, 41: 377-381, 2006. 
 23.  Ilias I and Pacak K. Diagnosis and management of tumors of the adrenal medulla, 
Horm Metab Res, 37: 717-721, 2005. 
 24.  Brodeur GM, Seeger RC, Barrett A, Berthold F, et al. International criteria for 
diagnosis, staging, and response to treatment in patients with neuroblastoma, J 
Clin Oncol, 6: 1874-1881, 1988. 
 25.  Brodeur GM, Pritchard J, Berthold F, Carlsen NLT, et al. Revisions of the 
international criteria for neuroblastoma diagnosis, staging, and response to 
treatment [see comments], J Clin Oncol, 11: 1466-1477, 1993. 
 114
 26.  Evans AE and D'Angio GJ. Age at diagnosis and prognosis in children with 
neuroblastoma, J Clin Oncol, 23: 6443-6444, 2005. 
 27.  London WB, Castleberry RP, Matthay KK, Look AT, et al. Evidence for an age 
cutoff greater than 365 days for neuroblastoma risk group stratification in the 
Children's Oncology Group, J Clin Oncol, 23: 6459-6465, 2005. 
 28.  George RE, London WB, Cohn SL, Maris JM, et al. Hyperdiploidy plus 
nonamplified MYCN confers a favorable prognosis in children 12 to 18 months 
old with disseminated neuroblastoma: a Pediatric Oncology Group study, J Clin 
Oncol, 23: 6466-6473, 2005. 
 29.  Schmidt ML, Lal A, Seeger RC, Maris JM, et al. Favorable prognosis for patients 
12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a 
Children's Cancer Group Study, J Clin Oncol, 23: 6474-6480, 2005. 
 30.  Schwab M, Alitalo K, Klempnauer KH, Varmus HE, et al. Amplified DNA with 
limited homology to myc cellular oncogene is shared by human neuroblastoma 
cell lines and a neuroblastoma tumour, Nature, 305: 245-248, 1983. 
 31.  Lee WH, Murphree AL, and Benedict WF. Expression and amplification of the 
N-myc gene in primary retinoblastoma, Nature, 309: 458-460, 1984. 
 32.  Nau MM, Brooks BJ, Jr., Carney DN, Gazdar AF, et al. Human small-cell lung 
cancers show amplification and expression of the N-myc gene, Proc Natl Acad 
Sci U S A, 83: 1092-1096, 1986. 
 33.  Grandori C and Eisenman RN. Myc target genes, Trends Biochem Sci, 22: 177-
181, 1997. 
 34.  Lutz W, Stohr M, Schurmann J, Wenzel A, et al. Conditional expression of N-
myc in human neuroblastoma cells increases expression of alpha-prothymosin and 
ornithine decarboxylase and accelerates progression into S-phase early after 
mitogenic stimulation of quiescent cells, Oncogene, 13: 803-812, 1996. 
 35.  Goodman LA, Liu BC, Thiele CJ, Schmidt ML, et al. Modulation of N-myc 
expression alters the invasiveness of neuroblastoma, Clin Exp Metastasis, 15: 
130-139, 1997. 
 36.  Maris JM and Matthay KK. Molecular biology of neuroblastoma, J Clin Oncol, 
17: 2264-2279, 1999. 
 37.  Shimada H, Chatten J, Newton WA, Jr., Sachs N, et al. Histopathologic 
prognostic factors in neuroblastic tumors: definition of subtypes of 
ganglioneuroblastoma and an age-linked classification of neuroblastomas, J Natl 
Cancer Inst, 73: 405-416, 1984. 
 115
 38.  Chatten J, Shimada H, Sather HN, Wong KY, et al. Prognostic value of 
histopathology in advanced neuroblastoma: a report from the Children's Cancer 
Study Group, Hum Pathol, 19: 1187-1198, 1988. 
 39.  Shimada H, Umehara S, Monobe Y, Hachitanda Y, et al. International 
neuroblastoma pathology classification for prognostic evaluation of patients with 
peripheral neuroblastic tumors: a report from the Children's Cancer Group, 
Cancer, 92: 2451-2461, 2001. 
 40.  Look AT, Hayes FA, Nitschke R, McWilliams NB, et al. Cellular DNA content as 
a predictor of response to chemotherapy in infants with unresectable 
neuroblastoma, N Engl J Med, 311: 231-235, 1984. 
 41.  Gansler T, Chatten J, Varello M, Bunin GR, et al. Flow cytometric DNA analysis 
of neuroblastoma. Correlation with histology and clinical outcome, Cancer, 58: 
2453-2458, 1986. 
 42.  Taylor SR, Blatt J, Costantino JP, Roederer M, et al. Flow cytometric DNA 
analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study, 
Cancer, 62: 749-754, 1988. 
 43.  Ladenstein R, Ambros IM, Potschger U, Amann G, et al. Prognostic significance 
of DNA di-tetraploidy in neuroblastoma, Med Pediatr Oncol, 36: 83-92, 2001. 
 44.  Nitschke R, Smith EI, Shochat S, Altshuler G, et al. Localized neuroblastoma 
treated by surgery: a Pediatric Oncology Group Study, J Clin Oncol, 6: 1271-
1279, 1988. 
 45.  Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, et al. Highly effective 
induction therapy for stage 4 neuroblastoma in children over 1 year of age, J Clin 
Oncol, 12: 2607-2613, 1994. 
 46.  Goldie JH and Coldman AJ. A mathematic model for relating the drug sensitivity 
of tumors to their spontaneous mutation rate, Cancer Treat Rep, 63: 1727-1733, 
1979. 
 47.  George RE, Li S, Medeiros-Nancarrow C, Neuberg D, et al. High-risk 
neuroblastoma treated with tandem autologous peripheral-blood stem cell-
supported transplantation: long-term survival update, J Clin Oncol, 24: 2891-
2896, 2006. 
 48.  Matthay KK, Villablanca JG, Seeger RC, Stram DO, et al. Treatment of high-risk 
neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone 
marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group, N 
Engl J Med, 341: 1165-1173, 1999. 
 116
 49.  Santana VM, Zamboni WC, Kirstein MN, Tan M, et al. A pilot study of 
protracted topotecan dosing using a pharmacokinetically guided dosing approach 
in children with solid tumors, Clin Cancer Res, 9: 633-640, 2003. 
 50.  Benedetti P, Fiorani P, Capuani L, and Wang JC. Camptothecin resistance from a 
single mutation changing glycine 363 of human DNA topoisomerase I to cysteine, 
Cancer Res, 53: 4343-4348, 1993. 
 51.  Fujimori A, Harker WG, Kohlhagen G, Hoki Y, et al. Mutation at the catalytic 
site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to 
camptothecin, Cancer Res, 55: 1339-1346, 1995. 
 52.  Dhooge CR, De Moerloose BM, Benoit YC, Van Roy N, et al. Expression of the 
MDR1 gene product P-glycoprotein in childhood neuroblastoma, Cancer, 80: 
1250-1257, 1997. 
 53.  de Cremoux P., Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, et al. Role of 
chemotherapy resistance genes in outcome of neuroblastoma, Pediatr Blood 
Cancer, 48: 311-317, 2006. 
 54.  Wall ME, Wani MC, Cook CE, and Palmer KH. Plant antitumor agents. I. The 
isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor 
inhibitor from Camptotheca acuminata, J Am Chem Soc, 88: 3888-3890, 1966. 
 55.  Gottlieb JA, Guarino AM, Call JB, Oliverio VT, et al. Preliminary pharmacologic 
and clinical evaluation of camptothecin sodium (NSC-100880), Cancer 
Chemother Rep, 54: 461-470, 1970. 
 56.  Muggia FM, Creaven PJ, Hansen HH, Cohen MH, et al. Phase I clinical trial of 
weekly and daily treatment with camptothecin (NSC-100880): correlation with 
preclinical studies, Cancer Chemother Rep, 56: 515-521, 1972. 
 57.  Moertel CG, Schutt AJ, Reitemeier RJ, and Hahn RG. Phase II study of 
camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer, 
Cancer Chemother Rep, 56: 95-101, 1972. 
 58.  Rivory LP and Robert J. Molecular, cellular, and clinical aspects of the 
pharmacology of 20(S)camptothecin and its derivatives, Pharmacol Ther, 68: 269-
296, 1995. 
 59.  Hertzberg RP, Caranfa MJ, Holdern KG, Jakas DR, et al. Modification of the 
hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I 
and biological activity, Journal of Medicinal Chemistry, 32: 715-720, 1989. 
 60.  Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond, Nat Rev 
Cancer, 6: 789-802, 2006. 
 117
 61.  Zamboni WC, Stewart CF, Thompson J, Santana VM, et al. Relationship between 
topotecan systemic exposure and tumor response in human neuroblastoma 
xenografts [see comments], J Natl Cancer Inst, 90: 505-511, 1998. 
 62.  Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, et al. Efficacy of topoisomerase I 
inhibitors, topotecan and irinotecan, administered at low dose levels in protracted 
schedules to mice bearing xenografts of human tumors, Cancer Chemother 
Pharmacol, 36: 393-403, 1995. 
 63.  Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, et al. Relationship between 
tumor extracellular fluid exposure to topotecan and tumor response in human 
neuroblastoma xenograft and cell lines, Cancer Chemother Pharmacol, 43: 269-
276, 1999. 
 64.  Pratt CB, Stewart CF, Santana VM, Bowman L, et al. Phase I study of topotecan 
for pediatric patients with malignant solid tumors, J Clin Oncol, 12: 539-543, 
1994. 
 65.  Blaney SM, Needle MN, Gillespie A, Sato JK, et al. Phase II trial of topotecan 
administered as 72-hour continuous infusion in children with refractory solid 
tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's 
Cancer Group Study, Clin Cancer Res, 4: 357-360, 1998. 
 66.  Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, et al. Phase I trial and 
pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a 
five-day course in children with refractory solid tumors: A Pediatric Oncology 
Group Study, J Ped Hem/Onc, 18: 352-361, 1996. 
 67.  Langler A, Christaras A, Abshagen K, Krauth K, et al. Topotecan in the treatment 
of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-
study, Klin Padiatr, 214: 153-156, 2002. 
 68.  Houghton PJ, Chesire PJ, Myers L, Stewart CF, et al. Evaluation of 9-
dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from 
adult and childhood solid tumors, Cancer Chemother Pharmacol, 31: 229-239, 
1992. 
 69.  Barthelmes HU, Habermeyer M, Christensen MO, Mielke C, et al. TDP1 
overexpression in human cells counteracts DNA damage mediated by 
topoisomerases I and II, J Biol Chem, 279: 55618-55625, 2004. 
 70.  Thompson J, Zamboni WC, Cheshire PJ, Lutz L, et al. Efficacy of systemic 
administration of irinotecan against neuroblastoma xenografts, Clin Cancer Res, 
3: 423-431, 1997. 
 71.  Thompson J, Zamboni WC, Cheshire PJ, Richmond LB, et al. Efficacy of oral 
administration of irinotecan against neuroblastoma xenografts., Anticancer Drugs, 
8: 313-322, 1997. 
 118
 72.  Vassal G, Terrier-Lacombe MJ, Bissery MC, Venuat AM, et al. Therapeutic 
activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive 
neuroectodermal tumour and neuroblastoma xenografts, Br J Cancer, 74: 537-545, 
1996. 
 73.  Mattern MR, Hofmann GA, Polsky RM, Funk LR, et al. In vitro and in vivo 
effects of clinically important camptothecin analogues on multidrug-resistant 
cells, Oncol Res, 5: 467-474, 1993. 
 74.  Jansen WJ, Hulscher TM, Ark-Otte J, Giaccone G, et al. CPT-11 sensitivity in 
relation to the expression of P170-glycoprotein and multidrug resistance-
associated protein, Br J Cancer, 77: 359-365, 1998. 
 75.  Houghton PJ, Stewart CF, Zamboni WC, Thompson J, et al. Schedule dependent 
efficacy of camptothecins in models of human cancer, New York Acad Sci, 803: 
188-201, 1996. 
 76.  Blaney S, Berg SL, Pratt C, Weitman S, et al. A phase I study of irinotecan in 
pediatric patients: a pediatric oncology group study, Clin Cancer Res, 7: 32-37, 
2001. 
 77.  Vassal G, Doz F, Frappaz D, Imadalou K, et al. A phase I study of irinotecan as a 
3-week schedule in children with refractory or recurrent solid tumors, J Clin 
Oncol, 21: 3844-3852, 2003. 
 78.  Mugishima H, Matsunaga T, Yagi K, Asami K, et al. Phase I study of irinotecan 
in pediatric patients with malignant solid tumors, J Pediatr Hematol Oncol, 24: 
94-100, 2002. 
 79.  Dean M, Rzhetsky A, and Allikmets R. The human ATP-binding cassette (ABC) 
transporter superfamily, Genome Res, 11: 1156-1166, 2001. 
 80.  Pleban K, Kopp S, Csaszar E, Peer M, et al. P-glycoprotein substrate binding 
domains are located at the transmembrane domain/transmembrane domain 
interfaces: a combined photoaffinity labeling-protein homology modeling 
approach, Mol Pharmacol, 67: 365-374, 2005. 
 81.  Higgins CF and Gottesman MM. Is the multidrug transporter a flippase?, Trends 
Biochem Sci, 17: 18-21, 1992. 
 82.  Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and 
Hinda Rosenthal Foundation Award Lecture, Cancer Res, 53: 747-754, 1993. 
 83.  Higgins CF and Linton KJ. The ATP switch model for ABC transporters, Nat 
Struct Mol Biol, 11: 918-926, 2004. 
 84.  Juliano RL and Ling V. A surface glycoprotein modulating drug permeability in 
Chinese hamster ovary cell mutants, Biochim Biophys Acta, 455: 152-162, 1976. 
 119
 85.  Molinari A, Calcabrini A, Meschini S, Stringaro A, et al. Subcellular detection 
and localization of the drug transporter P-glycoprotein in cultured tumor cells, 
Curr Protein Pept Sci, 3: 653-670, 2002. 
 86.  Petriz J, Gottesman MM, and Aran JM. An MDR-EGFP gene fusion allows for 
direct cellular localization, function and stability assessment of P-glycoprotein, 
Curr Drug Deliv, 1: 43-56, 2004. 
 87.  Gros P, Croop J, and Housman D. Mammalian multidrug resistance gene: 
complete cDNA sequence indicates strong homology to bacterial transport 
proteins, Cell, 47: 371-380, 1986. 
 88.  van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, et al. Distribution 
of multi-drug resistance-associated P-glycoprotein in normal and neoplastic 
human tissues. Analysis with 3 monoclonal antibodies recognizing different 
epitopes of the P-glycoprotein molecule, Ann Oncol, 1: 56-64, 1990. 
 89.  Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, et al. Effect of P-
glycoprotein expression on the accumulation and cytotoxicity of topotecan 
(SK&F 104864), a new camptothecin analogue, Cancer Res, 52: 2268-2278, 
1992. 
 90.  Hoki Y, Fujimori A, and Pommier Y. Differential cytotoxicity of clinically 
important camptothecin derivatives in P-glycoprotein-overexpressing cell lines, 
Cancer Chemother Pharmacol, 40: 433-438, 1997. 
 91.  Fojo AT, Ueda K, Slamon DJ, Poplack DG, et al. Expression of a multidrug-
resistance gene in human tumors and tissues, Proc Natl Acad Sci U S A, 84: 265-
269, 1987. 
 92.  Goldstein LJ, Fojo AT, Ueda K, Crist W, et al. Expression of the multidrug 
resistance, MDR1, gene in neuroblastomas, J Clin Oncol, 8: 128-136, 1990. 
 93.  Chan HS, Haddad G, Thorner PS, DeBoer G, et al. P-glycoprotein expression as a 
predictor of the outcome of therapy for neuroblastoma, N Engl J Med, 325: 1608-
1614, 1991. 
 94.  Chen G, Gharib TG, Huang CC, Taylor JM, et al. Discordant protein and mRNA 
expression in lung adenocarcinomas, Mol Cell Proteomics, 1: 304-313, 2002. 
 95.  Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, et al. Overexpression of a 
transporter gene in a multidrug-resistant human lung cancer cell line [see 
comments], Science, 258: 1650-1654, 1992. 
 96.  Kruh GD, Gaughan KT, Godwin A, and Chan A. Expression pattern of MRP in 
human tissues and adult solid tumor cell lines, J Natl Cancer Inst, 87: 1256-1258, 
1995. 
 120
 97.  Zaman GJ, Versantvoort CH, Smit JJ, Eijdems EW, et al. Analysis of the 
expression of MRP, the gene for a new putative transmembrane drug transporter, 
in human multidrug resistant lung cancer cell lines, Cancer Res, 53: 1747-1750, 
1993. 
 98.  Flens MJ, Zaman GJ, van d, V, Izquierdo MA, et al. Tissue distribution of the 
multidrug resistance protein, Am J Pathol, 148: 1237-1247, 1996. 
 99.  Deeley RG and Cole SP. Substrate recognition and transport by multidrug 
resistance protein 1 (ABCC1), FEBS Lett, 580: 1103-1111, 2006. 
 100.  Chen ZS, Furukawa T, Sumizawa T, Ono K, et al. ATP-Dependent efflux of CPT-
11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by 
PAK-104P, Mol Pharmacol, 55: 921-928, 1999. 
 101.  Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, et al. Extensive 
contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug 
resistance, Cancer Res, 60: 5761-5766, 2000. 
 102.  Toh S, Wada M, Uchiumi T, Inokuchi A, et al. Genomic structure of the 
canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and 
mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome, Am J 
Hum Genet, 64: 739-746, 1999. 
 103.  Buchler M, Konig J, Brom M, Kartenbeck J, et al. cDNA cloning of the 
hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals 
a novel conjugate export pump deficient in hyperbilirubinemic mutant rats, J Biol 
Chem, 271: 15091-15098, 1996. 
 104.  Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, et al. ATP-dependent 
transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and 
its hepatocyte canalicular isoform MRP2, Biochem J, 327 ( Pt 1): 305-310, 1997. 
 105.  Scheffer GL, Kool M, Heijn M, de Haas M, et al. Specific detection of multidrug 
resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with 
a panel of monoclonal antibodies, Cancer Res, 60: 5269-5277, 2000. 
 106.  Koike K, Kawabe T, Tanaka T, Toh S, et al. A canalicular multispecific organic 
anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human 
hepatic cancer cells, Cancer Res, 57: 5475-5479, 1997. 
 107.  Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, et al. Antifolate resistance 
mediated by the multidrug resistance proteins MRP1 and MRP2, Cancer Res, 59: 
2532-2535, 1999. 
 108.  Cui Y, Konig J, Buchholz JK, Spring H, et al. Drug resistance and ATP-
dependent conjugate transport mediated by the apical multidrug resistance 
 121
protein, MRP2, permanently expressed in human and canine cells, Mol 
Pharmacol, 55: 929-937, 1999. 
 109.  Chu XY, Kato Y, Niinuma K, Sudo KI, et al. Multispecific organic anion 
transporter is responsible for the biliary excretion of the camptothecin derivative 
irinotecan and its metabolites in rats, J Pharmacol Exp Ther, 281: 304-314, 1997. 
 110.  Norris MD, Smith J, Tanabe K, Tobin P, et al. Expression of multidrug 
transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and 
confers resistance to irinotecan in vitro, Mol Cancer Ther, 4: 547-553, 2005. 
 111.  Schuetz JD, Connelly MC, Sun D, Paibir SG, et al. MRP4: A previously 
unidentified factor in resistance to nucleoside- based antiviral drugs, Nat Med, 5: 
1048-1051, 1999. 
 112.  Jedlitschky G, Tirschmann K, Lubenow LE, Nieuwenhuis HK, et al. The 
nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and 
present in dense granules, indicating a role in mediator storage, Blood, 104: 3603-
3610, 2004. 
 113.  Kool M, de Haas M, Scheffer GL, Scheper RJ, et al. Analysis of expression of 
cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug 
resistance-associated protein gene (MRP1), in human cancer cell lines, Cancer 
Res, 57: 3537-3547, 1997. 
 114.  Leggas M, Adachi M, Scheffer GL, Sun D, et al. Mrp4 confers resistance to 
topotecan and protects the brain from chemotherapy, Mol Cell Biol, 24: 7612-
7621, 2004. 
 115.  van Aubel RA, Smeets PH, Peters JG, Bindels RJ, et al. The MRP4/ABCC4 gene 
encodes a novel apical organic anion transporter in human kidney proximal 
tubules: putative efflux pump for urinary cAMP and cGMP, J Am Soc Nephrol, 
13: 595-603, 2002. 
 116.  Zelcer N, Reid G, Wielinga P, Kuil A, et al. Steroid and bile acid conjugates are 
substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette 
C4), Biochem J, 371: 361-367, 2003. 
 117.  Chen ZS, Lee K, and Kruh GD. Transport of cyclic nucleotides and estradiol 17-
beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-
mercaptopurine and 6-thioguanine, J Biol Chem, 276: 33747-33754, 2001. 
 118.  Reid G, Wielinga P, Zelcer N, Van DH, I, et al. The human multidrug resistance 
protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by 
nonsteroidal antiinflammatory drugs, Proc Natl Acad Sci U S A, 100: 9244-9249, 
2003. 
 122
 119.  Chen ZS, Lee K, Walther S, Raftogianis RB, et al. Analysis of methotrexate and 
folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a 
component of the methotrexate efflux system, Cancer Res, 62: 3144-3150, 2002. 
 120.  Tian Q, Zhang J, Tan TM, Chan E, et al. Human multidrug resistance associated 
protein 4 confers resistance to camptothecins, Pharm Res, 22: 1837-1853, 2005. 
 121.  Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, et al. Cotransport of 
reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral 
hepatocyte membrane, Hepatology, 38: 374-384, 2003. 
 122.  Tian Q, Zhang J, Chan SY, Tan TM, et al. Topotecan is a substrate for multidrug 
resistance associated protein 4, Curr Drug Metab, 7: 105-118, 2006. 
 123.  Doyle LA, Yang W, Abruzzo LV, Krogmann T, et al. A multidrug resistance 
transporter from human MCF-7 breast cancer cells [published erratum appears in 
Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2569], Proc Natl Acad Sci U S A, 
95: 15665-15670, 1998. 
 124.  Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, et al. A human 
placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is 
involved in multidrug resistance, Cancer Res, 58: 5337-5339, 1998. 
 125.  Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, et al. Overexpression of 
the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line, 
Cancer Res, 59: 4559-4563, 1999. 
 126.  Kage K, Tsukahara S, Sugiyama T, Asada S, et al. Dominant-negative inhibition 
of breast cancer resistance protein as drug efflux pump through the inhibition of 
S-S dependent homodimerization, Int J Cancer, 97: 626-630, 2002. 
 127.  Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, et al. Subcellular 
localization and distribution of the breast cancer resistance protein transporter in 
normal human tissues, Cancer Res, 61: 3458-3464, 2001. 
 128.  Litman T, Brangi M, Hudson E, Fetsch P, et al. The multidrug-resistant 
phenotype associated with overexpression of the new ABC half-transporter, MXR 
(ABCG2), J Cell Sci, 113 ( Pt 11): 2011-2021, 2000. 
 129.  Houghton PJ, Germain GS, Harwood FC, Schuetz JD, et al. Imatinib mesylate is a 
potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to 
topotecan and SN-38 in vitro, Cancer Res, 64: 2333-2337, 2004. 
 130.  Stewart CF, Leggas M, Schuetz JD, Panetta JC, et al. Gefitinib enhances the 
antitumor activity and oral bioavailability of irinotecan in mice, Cancer Res, 64: 
7491-7499, 2004. 
 123
 131.  Abe T, Koike K, Ohga T, Kubo T, et al. Chemosensitisation of spontaneous 
multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human 
glioma cell lines overexpressing MRP or MDR1, Br J Cancer, 72: 418-423, 1995. 
 132.  Bai J, Lai L, Yeo HC, Goh BC, et al. Multidrug resistance protein 4 
(MRP4/ABCC4) mediates efflux of bimane-glutathione, Int J Biochem Cell Biol, 
36: 247-257, 2004. 
 133.  Leier I, Jedlitschky G, Buchholz U, Cole SP, et al. The MRP gene encodes an 
ATP-dependent export pump for leukotriene C4 and structurally related 
conjugates, J Biol Chem, 269: 27807-27810, 1994. 
 134.  Leier I, Hummel-Eisenbeiss J, Cui Y, and Keppler D. ATP-dependent para-
aminohippurate transport by apical multidrug resistance protein MRP2, Kidney 
Int, 57: 1636-1642, 2000. 
 135.  Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, et al. Characterization 
of the transport properties of human multidrug resistance protein 7 (MRP7, 
ABCC10), Mol Pharmacol, 63: 351-358, 2003. 
 136.  Leggas M, Panetta JC, Zhuang Y, Schuetz JD, et al. Gefitinib modulates the 
function of multiple ATP-binding cassette transporters in vivo, Cancer Res, 66: 
4802-4807, 2006. 
 137.  Hyafil F, Vergely C, Du VP, and Grand-Perret T. In vitro and in vivo reversal of 
multidrug resistance by GF120918, an acridonecarboxamide derivative, Cancer 
Res, 53: 4595-4602, 1993. 
 138.  Allen JD, van LA, Lakhai JM, van d, V, et al. Potent and specific inhibition of the 
breast cancer resistance protein multidrug transporter in vitro and in mouse 
intestine by a novel analogue of fumitremorgin C, Mol Cancer Ther, 1: 417-425, 
2002. 
 139.  Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, et al. Circumvention of 
breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in 
vitro using non-substrate drugs or the BCRP inhibitor GF120918, Clin Cancer 
Res, 7: 935-941, 2001. 
 140.  Allen JD, Brinkhuis RF, Wijnholds J, and Schinkel AH. The mouse 
Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for 
resistance to topotecan, mitoxantrone, or doxorubicin, Cancer Res, 59: 4237-
4241, 1999. 
 141.  Decleves X, Fajac A, Lehmann-Che J, Tardy M, et al. Molecular and functional 
MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines, 
Int J Cancer, 98: 173-180, 2002. 
 124
 142.  Fire A, Xu S, Montgomery MK, Kostas SA, et al. Potent and specific genetic 
interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391: 
806-811, 1998. 
 143.  Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, et al. RNA interference: 
biology, mechanism, and applications, Microbiol Mol Biol Rev, 67: 657-685, 
2003. 
 144.  Montgomery MK and Fire A. Double-stranded RNA as a mediator in sequence-
specific genetic silencing and co-suppression, Trends Genet, 14: 255-258, 1998. 
 145.  Dillin A. The specifics of small interfering RNA specificity, Proc Natl Acad Sci 
U S A, 100: 6289-6291, 2003. 
 146.  Zamore PD, Tuschl T, Sharp PA, and Bartel DP. RNAi: double-stranded RNA 
directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals, 
Cell, 101: 25-33, 2000. 
 147.  Ngo H, Tschudi C, Gull K, and Ullu E. Double-stranded RNA induces mRNA 
degradation in Trypanosoma brucei, Proc Natl Acad Sci U S A, 95: 14687-14692, 
1998. 
 148.  Montgomery MK, Xu S, and Fire A. RNA as a target of double-stranded RNA-
mediated genetic interference in Caenorhabditis elegans, Proc Natl Acad Sci U S 
A, 95: 15502-15507, 1998. 
 149.  Mittal V. Improving the efficiency of RNA interference in mammals, Nat Rev 
Genet, 5: 355-365, 2004. 
 150.  Semizarov D, Frost L, Sarthy A, Kroeger P, et al. Specificity of short interfering 
RNA determined through gene expression signatures, Proc Natl Acad Sci U S A, 
100: 6347-6352, 2003. 
 151.  Brummelkamp TR, Bernards R, and Agami R. A system for stable expression of 
short interfering RNAs in mammalian cells, Science, 296: 550-553, 2002. 
 152.  Castel V and Canete A. A comparison of current neuroblastoma 
chemotherapeutics, Expert Opin Pharmacother, 5: 71-80, 2004. 
 153.  Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, et al. Efficacy of topoisomerase I 
inhibitors, topotecan and irinotecan, administered at low dose levels in protracted 
schedules to mice bearing xenografts of human tumors, Cancer Chemother 
Pharmacol, 36: 393-403, 1995. 
 154.  Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, et al. Relationship between 
tumor extracellular fluid exposure to topotecan and tumor response in human 
neuroblastoma xenograft and cell lines, Cancer Chemother Pharmacol, 43: 269-
276, 1999. 
 125
 155.  Zamboni WC, Stewart CF, Thompson J, Santana VM, et al. Relationship between 
topotecan systemic exposure and tumor response in human neuroblastoma 
xenografts, Journal of National Cancer Institute, 90: 505-511, 1998. 
 156.  Norris MD, Bordow SB, Marshall GM, Haber PS, et al. Expression of the gene 
for multidrug-resistance-associated protein and outcome in patients with 
neuroblastoma, N Engl J Med, 334: 231-238, 1996. 
 157.  Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, et al. Transport of 
topoisomerase I inhibitors by the breast cancer resistance protein. Potential 
clinical implications, Ann N Y Acad Sci, 922: 188-194, 2000. 
 158.  Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, et al. Subcellular 
localization and distribution of the breast cancer resistance protein transporter in 
normal human tissues, Cancer Res, 61: 3458-3464, 2001. 
 159.  Amarzguioui M, Rossi JJ, and Kim D. Approaches for chemically synthesized 
siRNA and vector-mediated RNAi, FEBS Lett, 579: 5974-5981, 2005. 
 160.  Persons DA, Allay JA, Allay ER, Smeyne RJ, et al. Retroviral-mediated transfer 
of the green fluorescent protein gene into murine hematopoietic cells facilitates 
scoring and selection of transduced progenitors in vitro and identification of 
genetically modified cells in vivo, Blood, 90: 1777-1786, 1997. 
 161.  Adachi M, Sampath J, Lan LB, Sun D, et al. Expression of MRP4 confers 
resistance to ganciclovir and compromises bystander cell killing, J Biol Chem, 
277: 38998-39004, 2002. 
 162.  Wunderlich K, Zimmerman C, Gutmann H, Teuchner B, et al. Vasospastic 
persons exhibit differential expression of ABC-transport proteins, Mol Vis, 9: 
756-761, 2003. 
 163.  Assem M, Schuetz EG, Leggas M, Sun D, et al. Interactions between hepatic 
Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 
knockout mice, J Biol Chem, 279: 22250-22257, 2004. 
 164.  Zamber CP, Lamba JK, Yasuda K, Farnum J, et al. Natural allelic variants of 
breast cancer resistance protein (BCRP) and their relationship to BCRP 
expression in human intestine, Pharmacogenetics, 13: 19-28, 2003. 
 165.  Murray LJ, Bruno E, Uchida N, Hoffman R, et al. CD109 is expressed on a 
subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor 
cells, Exp Hematol, 27: 1282-1294, 1999. 
 166.  McKenzie PP, McPake CR, Ashford AA, Vanin EF, et al. MDM2 does not 
influence p53-mediated sensitivity to DNA-damaging drugs, Mol Cancer Ther, 1: 
1097-1104, 2002. 
 126
 167.  McPake CR, Tillman DM, Poquette CA, George EO, et al. Bax is an important 
determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 
expression and p53 status, Oncol Res, 10: 235-244, 1998. 
 168.  Middlemas DS, Stewart CF, Kirstein MN, Poquette C, et al. Biochemical 
correlates of temozolomide sensitivity in pediatric solid tumor xenograft models, 
Clin Cancer Res, 6: 998-1007, 2000. 
 169.  Friedenberg WR, Rue M, Blood EA, Dalton WS, et al. Phase III study of PSC-
833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone 
(valspodar/VAD) versus VAD alone in patients with recurring or refractory 
multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group, 
Cancer, 106: 830-838, 2006. 
 170.  Nobili S, Landini I, Giglioni B, and Mini E. Pharmacological strategies for 
overcoming multidrug resistance, Curr Drug Targets, 7: 861-879, 2006. 
 171.  Bates SE, Bakke S, Kang M, Robey RW, et al. A phase I/II study of infusional 
vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell 
carcinoma, Clin Cancer Res, 10: 4724-4733, 2004. 
 172.  Turner PK, Johnston B, Wingo S, Schuetz JD, et al. MRP4 and P-glycoprotein 
(PgP) expression associated with topotecan (TPT) sensitivity in neuroblastoma 
(NB) cell lines, Proc Am Assoc Cancer Res, 44: 2003. 
 173.  Graham C, Tucker C, Creech J, Favours E, et al. Evaluation of the antitumor 
efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase 
inhibitor depsipeptide in childhood cancer models in vivo, Clin Cancer Res, 12: 
223-234, 2006. 
 174.  Thompson J, Guichard SM, Cheshire PJ, Richmond LB, et al. Development, 
characterization and therapy of a disseminated model of childhood neuroblastoma 
in SCID mice, Cancer Chemother Pharmacol, 47: 211-221, 2001. 
 175.  Hausser HJ and Brenner RE. Phenotypic instability of Saos-2 cells in long-term 
culture, Biochem Biophys Res Commun, 333: 216-222, 2005. 
 176.  Maitra A, Arking DE, Shivapurkar N, Ikeda M, et al. Genomic alterations in 
cultured human embryonic stem cells, Nat Genet, 37: 1099-1103, 2005. 
 177.  Fiorani P and Bjornsti MA. Mechanisms of DNA topoisomerase I-induced cell 
killing in the yeast Saccharomyces cerevisiae, Ann N Y Acad Sci, 922: 65-75, 
2000. 
 178.  Kuo CC, Liu JF, and Chang JY. DNA repair enzyme, O6-methylguanine DNA 
methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase 
I inhibitors, J Pharmacol Exp Ther, 316: 946-954, 2006. 
 127
 179.  Hawley RG, Lieu FH, Fong AZ, and Hawley TS. Versatile retroviral vectors for 
potential use in gene therapy, Gene Ther, 1: 136-138, 1994. 
 180.  Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, et al. The stem cell 
marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with 
heme, J Biol Chem, 279: 24218-24225, 2004. 
 181.  De PK, Vandesompele J, Heimann P, Yigit N, et al. Human fetal neuroblast and 
neuroblastoma transcriptome analysis confirms neuroblast origin and highlights 
neuroblastoma candidate genes, Genome Biol, 7: R84-2006. 
 182.  Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, et al. Targeted expression of 
MYCN causes neuroblastoma in transgenic mice, EMBO J, 16: 2985-2995, 1997. 
 183.  Aigner A. Delivery Systems for the Direct Application of siRNAs to Induce RNA 
Interference (RNAi) In Vivo, J Biomed Biotechnol, 2006: 71659-2006. 
 184.  Simon T, Langler A, Berthold F, Klingebiel T, et al. Topotecan and etoposide in 
the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial, J 
Pediatr Hematol Oncol, 29: 101-106, 2007. 
 185.  Kushner BH, Kramer K, Modak S, and Cheung NK. Camptothecin analogs 
(irinotecan or topotecan) plus high-dose cyclophosphamide as preparative 
regimens for antibody-based immunotherapy in resistant neuroblastoma, Clin 
Cancer Res, 10: 84-87, 2004. 
 
 128
Vita 
Patricia Kellie Turner was born in Memphis, Tennessee on September 22, 1976. 
She attended Dogwood Elementary School and graduated from Houston High School in 
May, 1994. The following September she matriculated at Boston College and in May, 
1998 received the degree Bachelor of Science in Biochemistry. In August, 1998 she 
entered the Pharm.D./ Ph.D. program at the University of Tennessee Health Science 
Center and received the Pharm.D. degree in June, 2002. Upon successfully defending her 
dissertation in May 2007, she plans to begin a Cancer Research UK funded postdoctoral 
fellowship at the Northern Institute for Cancer Research at Newcastle University. Her 
postdoctoral research will be in the field of breast cancer pharmacokinetics, 
pharmacogenetics, pharmacodynamics, and population modeling. 
 129
